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ABSTRACT 
The first chapter of this dissertation provides an overview of the interdisciplinary 
Healthcare Genetics model, the framework for the studies described in Chapters Two, 
Three and Four. The model is comprised of five core constructs: Research, Environment, 
Clinical Practice, Ethical/Legal/Social Implications (ELSI) and Education. Each construct 
is defined. Chapter One also presents a brief overview of subsequent chapters.  
Chapter Two details a biophysical approach to the phenotypic classification of 
mutations in the 7-dehydroxycholesterol reductase (DHCR7) gene, involved in Smith-
Lemli-Opitz syndrome. This study utilized computer modeling to determine the 
biophysical effects of each mutation on structure and function of the DHCR7 protein.  
The third chapter is a narrative review of the role of the cytokine interleukin 17 
(IL-17) in the gynecological condition endometriosis. This review discusses the 
incidence, etiology and pathogenesis of endometriosis and outlines general guidelines for 
diagnosis and treatment are outlined. Finally, potential IL-17-targeted therapies are 
explored. 
Chapter Four presents original bench research that evaluated the effects of the 
phyto-cannabinoid beta-caryophyllene (BCP) on a cell culture model of endometriosis. 
The effects of BCP on markers of inflammation such as cell proliferation and vascular 
endothelial growth factor (VEGF) production were assessed. 
 The final chapter, Chapter Five, summarizes the findings from Chapters Two, 
Three and Four. The significance and limitations of these studies are discussed. Finally, 
Chapter Five provides recommendations for future research.
iii 
DEDICATION 
I would like to dedicate this dissertation to my family and friends for their 
continual support and encouragement throughout my years in the doctoral program. 
Thank you all so much for your love and prayers. I could not have reached this point 
without you! 
iv 
ACKNOWLEDGMENTS 
I would like to thank Dr. Julie Eggert, my long-time mentor for all her support 
throughout my years in the program. Thank you Dr. Eggert and Dr. Mary Beth Steck for 
remaining on my committee after retirement to see me through to the end of this process! 
I would like to thank Dr. Ann Wetsel for agreeing to be my committee chair after 
Dr. Eggert’s retirement. You have been so helpful, and your enthusiasm is contagious! 
Finally, I’d like to thank my committee member, Dr. Emil Alexov, for refusing to give up 
on the article that eventually became a chapter of this dissertation. Thank you all for your 
expertise, support and guidance through my dissertation process.   
I’d like to thank Yunhui Peng and Wenxing Zhang, my co-authors on Chapter 
Two of this dissertation. Also, thank you to Dr. Patilee Tate, Dr. Bruce Lessey and 
Angela Houwing for their assistance and support during the research detailed in Chapter 
Four.   
Finally, I would like to thank the faculty and staff of the Clemson University 
School of Nursing and my fellow Healthcare Genetics doctoral students. 
v 
TABLE OF CONTENTS 
Page 
TITLE PAGE .................................................................................................................... i 
ABSTRACT ..................................................................................................................... ii 
DEDICATION ................................................................................................................ iii 
ACKNOWLEDGMENTS .............................................................................................. iv 
LIST OF TABLES ......................................................................................................... vii 
LIST OF FIGURES ...................................................................................................... viii 
CHAPTER 
I. INTRODUCTION ......................................................................................... 1 
References ................................................................................................ 9 
II. COMPUTATIONAL INVESTIGATION OF THE MISSENSE
MUTATIONS IN DHCR7 GENE ASSOCIATED WITH SMITH-LEMLI-
OPITZ SYNDROME ............................................................................. 13 
Abstract .................................................................................................. 14 
Introduction ............................................................................................ 15 
Results and Discussion .......................................................................... 18 
Materials and Methods ........................................................................... 31 
Conclusions ............................................................................................ 39 
Abbreviations ......................................................................................... 41 
References .............................................................................................. 42 
III. THE EMERGING ROLE OF INTERLEUKIN 17 (IL-17) IN THE
PATHOGENESIS OF ENDOMETRIOSIS .......................................... 49 
Abstract .................................................................................................. 50 
Introduction ............................................................................................ 51 
Etiology and Pathogenesis of Endometriosis ......................................... 52 
Interleukin 17 (IL-17) ............................................................................ 55 
T helper 17 Cells Produce IL-17 ............................................................ 61 
vi 
Table of Contents (Continued)
Page 
Current Diagnosis and Treatment of Endometriosis .............................. 66 
The Role of IL-17 in Developing Future Treatments for 
      Endometriosis .................................................................................. 67 
Conclusion ............................................................................................. 68 
References .............................................................................................. 70 
Abbreviations ......................................................................................... 82 
IV. ASSESSMENT OF BETA-CARYOPHYLLENE (BCP) FOR THE
TREATMENT OF ENDOMETRIOSIS USING AN IN VITRO 
APPROACH .......................................................................................... 84 
Abstract .................................................................................................. 85 
Introduction ............................................................................................ 86 
Materials and Methods ........................................................................... 91 
Results .................................................................................................... 98 
Discussion ............................................................................................ 111 
References ............................................................................................ 115 
Abbreviations ....................................................................................... 126 
V. SUMMARY, LIMITATIONS AND RECOMMENDATIONS ................ 128 
Chapter Two......................................................................................... 128 
Chapter Three....................................................................................... 130 
Chapter Four ........................................................................................ 131 
References ............................................................................................ 134 
APPENDICES ............................................................................................................. 135 
A: Institutional Review Board (IRB) Documents ........................................... 136 
B: Permissions for Use ................................................................................... 144 
vii 
LIST OF TABLES 
Table        Page 
2.1 KNN Classifications and Polyphen Predictions of the 
Mutations with Unknown Effects .......................................................... 22 
2.2 RMSF Values Per Structural Region for Each Mutant ................................ 26 
 3.1 Inflammatory Factors Involved in Disease Progression Associated with 
IL-17 or Th17 Activities ........................................................................ 60 
4.1 Effects of BCP on Inflammatory Diseases .................................................. 88 
viii 
LIST OF FIGURES 
Figure       Page 
1.1 Interdisciplinary Healthcare Genetics Model ................................................ 3 
2.1 Visualization of Mutations Mapped onto DHCR7 Protein .......................... 20 
2.2 The Topology of the Cytosol Loops, the C Terminal Domain 
and Transmembrane Domains in DHCR7 Structure ............................. 24 
2.3 Residue Cross-Correlation ........................................................................... 28 
2.4 The Frequency Distribution of DHCR7 Mutations ...................................... 30 
2.5 Property Distance for All Types of Amino Acid Pairs ................................ 34 
3.1 Endometriosis Pathogenesis......................................................................... 53 
3.2 IL-17 Signaling ............................................................................................ 59 
3.3 Development of IL-17-Producing Th17 Cells ............................................. 63 
 4.1 Dose-Response of BCP on the Alkaline Phosphatase Activity in 
Ishikawa Cells ........................................................................................ 98 
 4.2 Dose-Response of BCP on the Alkaline Phosphatase Activity in 
RL95-2 Cells .......................................................................................... 99 
4.3 CyQUANT Proliferation Assay in Ishikawa Cells .................................... 100 
4.4 CyQUANT Proliferation Assay in RL95-2 Cells ...................................... 101 
4.5 Trypan Blue Assay in Normal ESCs ......................................................... 102 
4.6 Trypan Blue Assay in Endometriosis-Positive ESCs ................................ 103 
4.7 Trypan Blue Assay- Comparison of Normal and Endometriosis-Positive 
ESCs ..................................................................................................... 104 
4.8 Percent Change in Proliferation in Normal and Endometriosis-Positive 
ESCs ..................................................................................................... 105 
ix 
List of Figures (Continued) 
Figure Page 
4.9 VEGF ELISA in Endometriosis-Positive ESCs ........................................ 106 
4.10 Immunohistochemical Analysis of CB1 and CB2 in Endometrial 
Tissue Samples..................................................................................... 108 
4.11 7-AAD Flow Cytometry Analysis of ESCs Treated with BCP ................. 110 
4.12 Relative Expression of Cannabinoid Receptors in Ishikawa and 
RL95-2 Cells ........................................................................................ 111 
1 
CHAPTER ONE 
INTRODUCTION 
In 2003, the Human Genome Project was completed, providing the world with 
access to the sequence of most of the human genome and launching the field of genetics 
into the forefront of medicine (Human Genome Sequencing Consortium, 2004). 
Continuing from that time, genetic research has proliferated exponentially, resulting in 
ever-increasing understanding of the molecular basis of disease and the development of 
more cost-effective technologies with rapid availability of detailed results (Wilson & 
Nicholls, 2015). The impact of genetics on healthcare is far-reaching, offering the 
promise of disease prevention, early disease detection, and personalized therapies 
(Rabbani, Tekin, & Mahdieh, 2014). Healthcare genetics is an emerging discipline 
seeking to meet the challenges associated with the rapidly-expanding and evolving 
genetics landscape.  
This dissertation is comprised of five chapters with original research which 
illustrates and applies the Clemson University School of Nursing Healthcare Genetics 
(HCG) program model of interdisciplinary scholarship. In addition, the direct research 
topics in this dissertation are led by the HCG model constructs (see Figure 1.1). Chapter 
One introduces the HCG model and provides an overview of the dissertation chapters. 
Two important definitions, which serve as the foundation for this dissertation, are 
“exemplar” and “interdisciplinary research.” An exemplar is defined as “a person or thing 
serving as a typical example or excellent model” (Merriam-Webster.com, 2018). The 
2 
National Academy of Sciences, National Academy of Engineering, and Institute of 
Medicine (2005) defines interdisciplinary research as: 
 “A mode of research by teams or individuals that integrates information, data, 
techniques, tools, perspectives, concepts and/or theories from two or more disciplines 
or bodies of specialized knowledge to advance fundamental understanding or to solve 
problems whose solutions are beyond the scope of a single discipline or field of 
research practice” (p. 26). 
These studies, which comprise this dissertation, serve as models of interdisciplinary 
research, utilizing a variety of techniques from different disciplines. 
The theoretical foundation for this dissertation research is the HCG model (Figure 
1.1).  The HCG model was developed collaboratively by Healthcare Genetics PhD 
students and faculty in the theoretical foundations course (2014). The goal of the HCG 
program is to, “prepare interdisciplinary scientists to: collaborate with multiple 
disciplines to generate knowledge and develop theories that focus on the genomic aspects 
of actual and potential health problems, formulate health promotion, disease prevention 
and treatment strategies that translate and integrate genomic knowledge from a variety of 
disciplines and demonstrate leadership that facilitates interdisciplinary development and 
application of ethical guidelines and health policy in genetics.” (Healthcare Genetics 
Program Goals, 2018). New scientific and technological breakthroughs have been 
occurring at a rapid rate in the past decades, resulting in significant impacts in multiple 
areas of genetics. These genetic breakthroughs are constructs of the HCG model, 
including Clinical Practice, Education, Environment, Ethical, Legal and Social 
Implications (ELSI), and Research. While each construct has unique elements, the 
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constructs also contain shared elements, thus enabling identification of new areas of 
genetic information and/or application in areas of overlap.  
Figure 1.1. Interdisciplinary Healthcare Genetics Model 
 
Figure 1.1. The model is built using constructs of Research, Environment, Clinical 
Practice, Ethical/Legal/Social Implications (ELSI), and Education, (HCG, 2014).  
 
The Research construct, within the HCG model, is grounded in different research 
methods which include, but are not limited to, laboratory (bench) research, 
bioinformatics, biophysical research and applied research. Results from laboratory-based 
research enhance understanding of the mechanisms of disease at the molecular level. 
Bioinformatic and biophysical research employs computational techniques to analyze 
complex biological data such as DNA, ribonucleic acid (RNA) and protein sequences 
obtained from databases (Kucukkal et al., 2014). Applied research studies potentially 
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provide answers to issues associated with genetic diseases. e.g. developing safe and 
effective medications and medical devices to treat and/or manage a variety of health 
conditions (Coccia, 2018).  
The Environment construct includes the interaction of external factors with the 
genome or the epigenome. Factors that affect the genome may potentially directly change 
the DNA sequence, resulting in permanent changes. These factors may include exposure 
to ultraviolet (UV) radiation, chemicals, diet, exercise or encountering genome-altering 
viruses (Boskovic & Rando, 2018). These factors affect the epigenome by altering gene 
expression, but not the actual DNA sequence. These factors may result in a form of 
epigenetic modification, the methylation or demethylation of cytosine-guanine (CpG) 
dinucleotides near gene promoters. The addition of methyl groups typically silences gene 
expression while their removal increases gene expression (Koukoura, Sifakis, & 
Spandidos, 2016). Epigenetic changes have also been shown to have transgenerational 
effects (Boskovic & Rando, 2018). For example, the chronic inflammatory disease 
endometriosis is driven by the effects of estradiol while resisting the anti-inflammatory 
effects of progesterone. It has been shown that the progesterone receptor (PR) is 
hypermethylated while estrogen receptor (ER) is hypomethylated in women with 
endometriosis (Wu, Strawn, Basir, Halverson & Guo, 2006; Xue et al., 2007). Thus, it is 
essential that a HCP considers the interaction of genetic, epigenetic, environmental as 
well as the interactions among these three environmental factors.  These examples stress 
the importance of the Environment and the need for HCPs to consider and address 
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environmental interactions when evaluating a patient’s risk of disease and to determine 
the appropriate therapeutic course(s). 
The Clinical Practice construct represents the area in which genetic research is 
applied with the goal of positively impacting health outcomes. In this construct, HCPs, 
clinicians and other professionals utilize their knowledge about the genetics of disease to 
screen, diagnose, and prescribe therapeutic regimens based on the results their genetic 
information (family history and genetic test results) (Slomp, Morris, Inglis, Lehman & 
Austin, 2018).  HCPs must be knowledgeable about availability of genetic tests, how 
these tests are ordered, and their accurate interpretation to ensure optimal health 
outcome(s) for their patients. It is also important that HCPs stay abreast of new DNA-
based therapies and how these therapies are implemented.   
As a part of Clinical Practice, patients and their families must be aware that 
Environment, including lifestyle factors, influences their genetic/genomic health.  
Inclusion of lifestyle highlights the importance of patients and families making informed 
healthcare decisions.  The healthcare team also educates/counsels patients and their 
families on a variety of issues, e.g. the likelihood that a couple could have a child with a 
disease or an individual’s risk of developing disease. For example, a family with a history 
of physical malformations and intellectual disability may undergo genetic testing for a 
panel of diseases, including Smith-Lemli-Opitz syndrome (Kalsner et al., 2018).  Health 
promotion and disease prevention are other important constructs of clinical care 
involving genetics (Slomp, Morris, Inglis, Lehman & Austin, 2018). Patient and Family 
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educational needs are one example of the overlap between Education with Clinical 
Practice. 
At the same time, genetic science and technological advances have outpaced the 
Ethical, Legal and Social (ELS) understanding, increasing the potential for harmful 
implications/impacts on an individuals and families. Ethical, Legal and Social 
Implications were identified/existed prior to the Human Genome project, as researchers 
were already aware that these issues would arise from the application of the new genetic 
knowledge (Clayton, 2003). While ELSI is recognized as being an important construct in 
the HCG model, it is not a focus in this dissertation research.  
The fifth construct is Education.  It is essential that everyone, from healthcare 
providers to the public, become knowledgeable in the basic principles of heredity and the 
role that an individual’s deoxyribonucleic acid (DNA) plays in their overall health status.  
Thus, it is crucial that genetic education is required in curricula at all academic levels, 
beginning in the primary grades and extending through high school, community/technical 
college, and undergraduate education (Talwar, Tseng, Foster, Xu & Chen, 2017). 
Genetics is recognized as a major content area in the educational programs of healthcare 
professionals (REF nursing & medicine).  In addition, the importance of continuing 
education in genetics be emphasized, as the field is expanding so rapidly. This overlap 
emphasizes the importance of teaching families and patients with a genetic disease 
diagnosis.   
Chapter Two explores the effects of various point mutations on the 
conformational stability of the 7-dehydroxycholesterol reductase (DHCR7) protein via 
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computer protein modelling. The DHCR7 protein is associated with Smith-Lemli-Opitz 
syndrome (SLOS), a cholesterol synthesis disorder (Smith, Lemli, & Opitz, 1964).  
Bioinformatic and biophysical techniques were used to locate, collect and analyze 
publicly-available DNA and protein data using methods that discriminate between 
disease-causing and benign DHCR7 mutations. Ten mutations (five pathogenic, two 
benign and three with unknown effects), that occur in the protein, underwent an extensive 
atom-by-atom molecular dynamic simulation to determine the effects of the mutations on 
protein conformational dynamics. In this analysis, the mutated protein was compared to 
the normal protein using a computer simulation program representing the actual 
intracellular environment where the DHCR7 enzyme resides. (Peng, Myers, Zhang, & 
Alexov, 2018). 
Chapter Three reviews literature surrounding the role of the pro-inflammatory 
cytokine interleukin 17 (IL-17) and its primary cellular source, T-helper 17 (Th17) cells, 
in endometriosis. The IL-17 pathway and its function in the initiation of inflammation are 
examined. The incidence, etiology and pathogenesis of endometriosis plus available 
treatments and their limitations are discussed. General guidelines for diagnosis and 
treatment are presented (Armstrong, 2011; Journal of Obstetrics and Gynaecology 
Canada [JOGC], 2010). Finally, the potential for future treatments targeted to the IL-17 
pathway and clinical research are explored.  
Chapter Four reports original bench research that assessed the effects of the 
cannabinoid beta-caryophyllene (BCP) on a cell culture model of endometriosis. Beta-
caryophyllene, produced by plants such as oregano and basil as well as Cannabis sativa, 
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initiates an anti-inflammatory response without the psychotropic effects of cannabis. This 
makes it attractive as a potential therapy to treat the chronic inflammation associated with 
endometriosis. Two endometrial cancer cell lines, as well as primary human endometrial 
cells from women with and without endometriosis, served as biological models for this 
research. Cells were cultured with proinflammatory factors to induce inflammation, then 
treated with or without beta-caryophyllene to determine effects on markers of 
inflammation (estrogen and vascular endothelial growth factor (VEGF)). Effects of BCP 
on cell proliferation and cell viability were also investigated.  
Chapter Five provides a summary of the findings from the individual dissertation 
research studies.  A discussion of the HCG model, as the foundation for these research 
exemplars, is presented.  The limitations and significance of these studies is also 
discussed.  Chapter Five concludes with recommendations for future research in the 
emerging field of healthcare genetics. 
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CHAPTER TWO 
COMPUTATIONAL INVESTIGATION OF THE MISSENSE MUTATIONS IN 
DHCR7 GENE ASSOCIATED WITH SMITH-LEMLI-OPITZ SYNDROME 
Yunhui Peng , Rebecca Myers , Wenxing Zhang and Emil Alexov 
(Published in International Journal of Molecular Science, January 2018, 19, 141.) 
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Abstract: Smith-Lemli-Opitz syndrome (SLOS) is a cholesterol synthesis disorder 
characterized by physical, mental, and behavioral symptoms. It is caused by mutations 
in 7-dehydroxycholesterolreductase gene (DHCR7) encoding DHCR7 protein, which is 
the rate-limiting enzyme in the cholesterol synthesis pathway. Here we demonstrate that 
pathogenic mutations in DHCR7 protein are located either within the transmembrane 
region or are near the ligand-binding site and are highly conserved among species. In 
contrast, non-pathogenic mutations observed in the general population are located 
outside the transmembrane region and have different effects on the conformational 
dynamics of DHCR7. All together, these observations suggest that the non-classified 
mutation R228Q is pathogenic. Our analyses indicate that pathogenic effects may affect 
protein stability and dynamics and alter the binding affinity and flexibility of the binding 
site. 
Keywords: Smith-Lemli-Opitz syndrome; missense mutations; DHCR7; binding free 
energy; folding free energy; KNN classification; molecular dynamics simulation; 
MM/PBSA 
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1. Introduction 
Smith-Lemli-Opitz syndrome (SLOS) is an inherited disorder of cholesterol 
synthesis characterized by intellectual disability and multiple malformations, including 
facial and genital abnormalities and syndactyly and was first described by Smith and 
coworkers [1]. The reported incidence of SLOS varies widely depending on the 
heterogeneity of the population studied, the biochemical methods used and the alleles 
assessed. Current estimates of SLOS carrier frequency in Caucasian populations lie 
between 1% and 3% [2–4]. SLOS is more prevalent in individuals of northern and eastern 
European descent and is rarely described in individuals of Asian or African descent [5]. 
Reports that up to 80% of affected fetuses, likely those heterozygous for null mutations, 
die before birth and that milder cases of the disease may not be diagnosed, conceivably 
prevent accurate determination of frequency [6–8]. The majority of “classical” SLOS 
patients are compound heterozygotes with one severe null mutation and a second 
missense mutation which retains some enzyme functionality. Milder cases often possess 
two less severe missense mutations [9]. 
SLOS is linked to mutations in 7-dehydroxycholesterol reductase (DHCR7), which is 
the rate-limiting enzyme in the cholesterol synthesis pathway [10]. DHCR7 reduces the 
C7–C8 double bond of 7-dehydrocholesterol (7DHC), the precursor molecule to 
cholesterol [11]. Cholesterol, though harmful in high levels, is essential to life since it is 
involved in membrane structure and permeability, synthesis of steroid hormones and 
proper fetal development. The loss of functionality of the DHCR7 enzyme in individuals 
with SLOS results in a significant decrease in cholesterol levels and possibly toxic 
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buildup of 7DHC and other cholesterol precursors [12]. It was shown that accumulation 
of 7DHC in the brains of rats is associated with intellectual and learning disabilities 
[13,14]. 
In addition to its role in cholesterol synthesis, 7DHC is also required for vitamin D3 
production. Exposure to sunlight cleaves the C9–C10 bond of 7DHC in the skin, resulting 
in vitamin D3. Vitamin D3 is essential for calcium absorption and bone health [13]. As 
DHCR7 activity decreases the amount of 7DHC available for vitamin D3 synthesis, there 
is a potential heterozygote advantage to carriers of DHCR7 mutations, which typically 
decrease enzymatic activity [14,15]. This may explain the prevalence of mutations 
originating in areas with decreased sun exposure such as northern Europe and northeast 
Asia [7,16]. 
The DHCR7 gene maps to chromosome 11q13.2–13.5 [17–19] and consists of nine 
exons with the initiation codon located in exon three. The gene is expressed in all tissues 
with peak expression in adrenal glands, liver and brain [17]. DHCR7 encodes a 475 
amino acid polypeptide with a molecular weight of 54.5 kDa, which is a transmembrane 
protein located in the endoplasmic reticulum (ER) membrane, the location of cholesterol 
synthesis. 
The first DHCR7 mutations were identified in 1998 by several groups and the early 
years of the 21st century resulted in more advanced molecular tests to rapidly identify 
DHCR7 mutations [17,18]. Most mutations are identified through sequence analysis of 
coding exons and flanking intronic sequences [5,17]. To date, more than 160 DHCR7 
mutations have been reported [5]. The most common mutation with a prevalence of 
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~30% of reported SLOS patients is the IVS8AS G > C − 1 splice acceptor site mutation. 
This results in the inclusion of 134 base pairs of intronic sequence into the transcript and 
a non-functional protein. Other common mutations include T93M, W151X, V326L and 
R404C.  
The majority of pathogenic DHCR7 mutations occur in the highly conserved C-
terminus region of the protein. In their molecular model of the DHCR7 protein, Li and 
coworkers predicted two overlapping binding sites: one for docking of the sterol 7DHC 
and one for binding of the coactivator NADPH [19]. As both binding sites are critical for 
proper protein function, it can be speculated that mutations affecting these areas would be 
most likely to result in disease. In support of this hypothesis, Waterham and Hennekam 
conducted a systematic review of published SLOS patients and compared genotype with 
phenotype [5]. They concluded that the most severely affected patients presented with 
two null alleles or two mutations in the 8–9 cytoplasmic loop while a milder phenotype 
was associated with mutations in the 1–2 loop or one mutation in the N- or C-terminus 
[5]. 
In the present study, we obtained variations in the DHCR7 gene from online 
databases and modelled their effects on the corresponding protein to make predictions 
about SLOS phenotype. We demonstrate that structural and conservation properties are 
good discriminators between pathogenic and non-pathogenic mutations, while folding 
free energy changes (∆∆Gs) are not. This is consistent with previous observations [20] 
that current methodology for computing ∆∆Gs are not accurate enough when applied to 
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membrane proteins. Furthermore, based on detailed analysis of selected mutants, we 
predict that the currently non-classified mutation, R228Q, is pathogenic. 
2. Results and Discussion 
2.1. Mapping Missense Mutations onto the 3D Structure of DHCR7 Protein 
The dataset of DHCR7 missense mutations includes three types of mutations: 
pathogenic, non-pathogenic and mutations of unknown effect. The mutations were 
visualized by mapping them onto the DHCR7 structure (Figure 2.1A). Pathogenic 
mutations are predominantly located in transmembrane and ligand-binding regions while 
non-pathogenic mutations are primarily situated outside the membrane. This observation 
indicates that pathogenic mutations occur at protein sites that are either buried or directly 
involved in protein function, which corroborates the findings of previous investigations 
[21–24]. To investigate the linkage between structural and evolutionary features of 
DHCR7 protein, we obtained the evolutionary conservation score (EC score) for each 
residue from multiple sequence alignment and mapped them onto the 3D structure of 
DHCR7 (Figure 2.1B). The transmembrane and ligand-binding regions appear to be 
highly conserved. Thus, most pathogenic mutations are located in highly conserved 
positions, while non-pathogenic mutations are less conserved. To further quantitatively 
assess the mutations’ effects, we computed the relative solvent accessible surface area 
(rSASA), evolutionary conservation score (EC score) and folding free energy change 
(∆∆G) for all mutations studied in this work (Table S1). Pathogenic mutations tend to 
have lower rSASA values and higher EC scores compared with non-pathogenic 
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mutations. However, ∆∆G results show no obvious tendency to discriminate pathogenic 
from non-pathogenic mutations. The predictions made with different servers frequently 
contradict each other resulting in large standard deviation (SD) when averaging these 
predictions (Table S1). As DHCR7 is a transmembrane protein and recent work [20] 
demonstrated that current tools of ∆∆G predictions are not accurate when applied to 
membrane proteins, this may explain why ∆∆G fails to discriminate pathogenic from 
non-pathogenic mutations in this case. In addition, we also performed Polyphen 
predictions on all types of mutations (Table S1). Almost all the pathogenic mutations are 
predicted to be probably damaging by Polyphen. However, Polyphen overestimated the 
deleteriousness of the non-pathogenic mutations. About half of the non-pathogenic 
mutations were classified as possibly or probably damaging. Thus, Polyphen has limited 
accuracy in discriminating the pathogenic mutations from the mutations with unknown 
effects for this particular protein. 
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Figure 2.1. (A) Visualization of mutations mapped onto DHCR7 protein. Red, 
orange and green colored sites represent pathogenic, unknown effects and non-
pathogenic mutations, respectively. The membrane boundaries are schematically 
shown with light blue dashed lines; (B) Most highly evolutionarily conserved 
residues mapped onto DHCR7 protein. Residues with EC score > 0.9 are marked 
with blue and all mutation-affected residues are shown with side chain. The 
membrane boundaries are schematically shown with light blue dashed lines. 
2.2. Classification of the Mutations with Unknown Effects Using KNN Model 
One of the goals of this study was to identify biophysical features allowing us to 
distinguish between pathogenic and non-pathogenic mutations, and thus to make 
predictions about unclassified mutations. Above, we outlined several biophysical 
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features, namely rSASA, EC score, PD and ΔΔG, which will be used in conjunction with 
the K-nearest neighbors (KNN) method (see Method section). The dataset includes 16 
pathogenic mutations and 23 non-pathogenic mutations. These 39 mutations were 
randomly partitioned into training dataset (29 mutations) and test dataset (10 mutations) 
and then subjected to the KNN classifications. As the ΔΔG was shown to be less 
successful in distinguishing between pathogenic and non-pathogenic mutations, we 
performed the KNN classification with and without the ΔΔG (Table S2). The 
classification shows better performance without using the ΔΔG and the accuracy is 100% 
when K value is within 5 to 9. Here, we select K = 7 (the median of the K value 
corresponding to highest accuracy). Finally, KNN model with K = 7 and using properties: 
rSASA, EC score and PD applied to classify the mutations with unknown effects (Table 
2.1). Thus, we predict that among all currently known unclassified mutations, only 
R228Q is pathogenic. In Table 2.1 we also compared our KNN classification results with 
the predictions from Polyphen. Consistent with our results, Polyphen predicted R228Q to 
be probably damaging. However, Polyphen gives contradictory predictions for eight 
additional mutations (predicted to be probably damaging), which are classified as non-
pathogenic by our KNN classification. Overestimation of mutation deleteriousness was 
also observed when applying Polyphen to the known non-pathogenic mutations (Table 
S1). 
Table 2.1. KNN classifications and Polyphen predictions of the mutations with 
unknown effects. P and N represent pathogenic and non-pathogenic mutations, 
respectively. 
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Mutation
KNN 
Classification Polyphen Mutation
KNN 
Classification Polyphen 
A41V N Benign R228Q P 
Probably 
damaging 
I44T N Benign V330M N 
Probably 
damaging 
A67T N 
Possibly 
damaging 
V338M N Benign 
I75F N Benign F361L N 
Probably 
damaging 
R81W N 
Probably 
damaging 
T364M N 
Probably 
damaging 
A97T N 
Possibly 
damaging 
R367C N 
Probably 
damaging 
V126I N 
Probably 
damaging 
G424S N 
Probably 
damaging 
V134L N Benign G425S N Benign 
A162V N 
Possibly 
damaging 
R461C N 
Probably 
damaging 
2.1 Case Study of Selected Mutations Using Molecular Dynamics (MD) Simulations 
The above classification and analyses were performed using fast computational 
approaches and were applied to the entire dataset. We selected a subset of mutations for 
extensive MD simulations to investigate the possibility that pathogenic and non-
pathogenic mutations have different effects on DHCR7 protein conformational dynamics. 
For this purpose, we selected 10 representative mutations including five pathogenic 
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mutations (T154R, E288K, T289I, G303R and R404C), two non-pathogenic mutations 
(R260Q and A452T) and three mutations with unknown effects (V134L, R228Q and 
F361L). These mutations are localized to different regions of protein structure. Five 
mutations (T154R, R228Q, E288K, T289I and G303R) are located in the transmembrane 
region and are buried in the membrane, two mutations (F361 and R404C) occur near the 
ligand-binding site and potentially affect ligand binding, and the remaining three 
mutations (V134, R260Q and A452T) are in neither the transmembrane region nor the 
ligand binding site. 
Since our focus was on protein conformational dynamics, we calculated the 
corresponding RMSDs and RMSFs for the wild type and mutant proteins. The average 
RMSD data shows no obvious difference between wild type protein and proteins with 
non-pathogenic or pathogenic mutations. However, the average RMSF indicates some 
differences between the wild type and mutants. For example, in the mutant A452T, 
cytosol loops (CL) 2 and 4 and transmembrane domain (TM) 10 regions are more rigid 
compared to the wild type (Table 2.2). However, no apparent patterns were identified to 
differentiate pathogenic mutations and non-pathogenic mutations by simply observing the 
graphs. A previous study of the AGAL protein has indicated a correlation between the 
protein’s flexibility and the severity of a mutant’s pathogenicity [25]. Thus, to identify 
such potential correlation in DHCR7 protein, we mapped the pathogenic and non-
pathogenic mutations on the average RMSF of the wild type proteins (shown in Figure 
S1). We observed that most pathogenic mutations are located on the low RMSF region 
while the non-pathogenic mutations show the opposite trend. As the low RMSF residues 
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are mostly transmembrane, such observed correlation is expected when majority of the 
pathogenic mutations are located on the transmembrane region. In addition, further 
analysis was performed by grouping the residues into different regions and then summing 
up the RMSF of residues in that region to get a region-RMSF. Based on DHCR7 protein 
structure information [26], residues were grouped into regions: TM1 (residues 40–60), 
TM2 (residues 94–115), TM3 (residues 145–164), TM4 (residues 176–191), TM5 
(residues 235–256), TM6 (residues 268–288), TM7 (residues 302–326), TM8 (residues 
332–352), TM9-10 (residues 408–442), CL1 (residues 116–144), CL2 (residues 198–
234), CL3 (residues 289–301), CL4 (residues 354–407) and CTD (residues 443–475). 
The topology of the cytosol loops (CL), the C terminal domain (CTD) and 
transmembrane domains (TM) mapped with selected mutations are further represented 
for better visualization of the DHCR7 structure (Figure 2.2). 
Figure 2.2. The topology of the cytosol loops (CL), the C terminal domain 
(CTD) and transmembrane domains (TM) in DHCR7 structure. Mutation sites 
are mapped with different colors according to mutation type (double color is 
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applied for sites with unknown and non-pathologic classification). The 
unclassified mutation R228Q, which we predict to be pathogenic, is highlighted 
with a red asterisk. 
Table 2.2 shows the region-RMSFs. Pathogenic mutations tend to decrease the 
flexibility in the TM1, TM2 and CL2 regions and increase the flexibility in the TM7 and 
TM9-10 regions. Very little is known about DHCR7 function and structural changes 
occurring during chemical reactions, so we used the above observation to suggest an 
empirical formula that discriminates between pathogenic and non-pathogenic mutations, 
which were subjected to MD simulations (ideally, one should perform such an analysis 
for mutations analyzed in this manuscript, but this is too computationally demanding). 
For the wild type and each mutant, we sum the RMSFs of TM1, TM2 and CL2 and then 
subtract the RMSFs of TM7 and TM9_10 (last column in Table 2.2). We refer to this 
quantity as cumulative RMSF. The wild type and non-pathogenic mutants have 
cumulative RMSFs larger than 50 Å while all pathogenic mutants have a cumulative 
RMSF less than or equal to 46 Å. Among non-classified mutations, V134L is confirmed 
to be non-pathogenic, while R228Q and F361L show the same cumulative RMSFs as 
pathogenic mutations. Thus, it is encouraging to observe that R228Q is independently 
confirmed to be pathogenic mutation (see KNN classification above), while F361L 
cannot be classified with high confidence and additional investigations are reported in the 
next section. 
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Table 2.2. RMSF values per structural region (see text for details) for each of the mutants. The RMSFs are given in Å units. The 
last column reports the RMSF calculated as the sum of RMSFs of TM1, TM2 and CL2 subtracted by RMSF of TM7 and TM9-
10. Values larger than 50 Å are underlined.
Pathogenic Missense Mutations 
TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM8 TM9_10 CL1 CL2 CL3 CL4 CTD TM1+TM2-TM7-TM9_10+CL2 
T154R 22.9 17.6 15.5 9.1 14.5 17.4 17.2 17.8 31.6 53.1 48.6 8.8 78.8 30.8 40.3 
E288K 19.6 16.4 16.0 10.5 13.1 14.3 16.0 18.4 26.1 49.2 38.6 13.6 77.5 32.0 32.7 
T289I 25.2 18.0 17.8 12.8 14.1 14.3 19.5 17.5 28.7 50.1 47.9 10.1 71.1 30.4 42.9 
G303R 21.1 18.9 16.8 11.0 13.3 16.0 18.2 17.0 30.2 50.5 49.2 10.4 65.0 30.1 40.9 
R404C 23.4 16.5 16.0 10.8 16.0 16.8 20.8 23.3 31.6 48.9 57.4 10.0 80.1 32.7 44.9 
Missense Mutations with Unknown Effects 
TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM8 TM9_10 CL1 CL2 CL3 CL4 CTD TM1+TM2-TM7-TM9_10+CL2 
V134L 20.1 21.1 18.8 11.0 14.7 13.6 16.6 16.2 27.7 52.9 53.4 11.0 79.7 35.6 50.3 
R228Q 17.6 17.0 15.9 8.5 13.6 13.0 15.6 16.9 27.6 53.2 54.2 10.7 75.8 36.7 45.6 
F361L 19.4 17.4 14.8 9.9 14.2 14.0 18.3 16.6 28.8 54.7 50.8 11.7 74.8 33.5 40.5 
Non-Pathogenic Missense Mutations 
TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM8 TM9_10 CL1 CL2 CL3 CL4 CTD TM1+TM2-TM7-TM9_10+CL2 
R260Q 19.7 18.6 15.5 9.4 12.9 14.6 15.4 17.2 24.4 58.4 52.1 11.4 79.3 28.1 50.6 
A452T 20.9 19.6 17.8 10.5 13.6 16.2 16.4 17.2 26.0 55.2 52.8 8.7 66.6 30.1 51.0 
Wild Type 
TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM8 TM9_10 CL1 CL2 CL3 CL4 CTD TM1+TM2-TM7-TM9_10+CL2 
WT 18.2 18.3 17.9 10.7 16.3 16.0 18.5 18.1 31.1 51.9 65.1 13.0 80.4 37.8 52.0 
2
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2.4. Analysis of Mutations’ Pathogenic Effects: 
2.4.1. Ligand Binding 
Here, we investigated the possibility that mutations may change DHCR7 
functionality by altering the binding affinity towards its ligand NADPH. For this purpose, 
we compared the effects of F361L (non-classified) and R404C (pathogenic mutation), 
both located near the NADPH binding site. It is anticipated that NADPH binding will 
cause structural rearrangement of the binding site and the conformational flexibility of 
the binding pocket is essential for proper protein function. We tested the effects of F361L 
and R404C on binding pocket flexibility by comparing them with the wild type protein. 
This was done using the MD trajectories obtained above and computing the residue 
cross-correlation for each trajectory with Bio3D [27]. These types of analyses were 
successfully used to elucidate the effects of a single mutation on the human β2-
microglobulin’s protein dynamics [28]. For each mutation and wild type, we calculated 
the average cross-correlation from three independent MD runs. Finally, the residue cross-
correlation changes for mutations F361L and R404C are shown in Figure 2.3A,B, which 
is the subtraction of the averaged cross-correlation map between mutant and wild type 
proteins. Significant changes of the cross-correlation coefficient near the NADPH 
binding site were found for R404C, highlighted with a circle in Figure 2.2, but not for 
F361L. 
We also performed MM/PBSA analysis to investigate the effect of mutations on 
NADPH binding affinity (Figure 2.3D). Mutation R404C results in a large increase of the 
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binding affinity by about 15 kcal/mol. As shown in the literature [21,29,30], any large 
deviation from wild type characteristics may be deleterious. In this case, R404C 
mutations contribute to disease by altering the binding affinity of NADPH. Compared to 
the effect of F361L, we observe that binding affinity is much less affected. This, 
combined with correlation analysis, allows us to speculate that F361L is a non-
pathogenic mutation. 
 
Figure 2.3. (A–C) The changes in residue cross-correlation for mutations 
F361L, R404C and R228Q; (D) NADHP binding free energy for WT and 
mutations F361L and R404C. 
2.4.2. Protein Dynamics 
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We further analyzed the selected mutations including our predicted pathogenic 
mutation R228Q to identify other pathogenic effects on protein functionality. The residue 
cross-correlation analysis of R228Q (Figure 2.2C) indicates a local conformational 
change near the mutation site. The R228Q mutation makes the corresponding region 
more rigid, resulting in local flexibility changes in CL2. Changes in protein dynamics are 
also observed in the residue cross-correlation analysis of other pathogenic mutations such 
as E288K and G303R (shown in Figure S2), indicating that alterations in DHCR7 protein 
dynamics likely contribute to protein dysfunction.  
2.5. Allele Frequency Analysis 
We compared the frequency distribution of pathogenic mutations and frequently-
occurring common mutations among different populations and genders. Figure 2.4A 
displays the top 40 DHCR7 mutations of varying types occurring in more than 50 
individuals archived in the ExAC database. At the same time, Figure 2.3B shows the 
distribution of pathogenic missense mutations chosen for this study within the same set of 
populations. The most frequently-occurring mutations in the general population are found 
in individuals of non-Finnish European descent followed by South Asian and African and 
African American descent (Figure 2.4A). Additionally, individuals of non-Finnish 
European and South Asian descent have the highest frequency of pathogenic mutations as 
shown in Figure 2.4B. African and African American populations have few cases of 
SLOS despite high occurrences of DHCR7 mutations. The low occurrence and frequency 
of mutations in Europeans of Finnish descent is supported by the extremely low number 
of SLOS cases in Finland [31]. 
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Interestingly, females in the overall ExAC population possess more DHCR7 
mutations at higher frequencies than males (Figure 2.4C), while this is an opposite for the 
pathogenic mutations investigated in this manuscript (Figure 2.4D), though no support 
for this trend has been found in the literature. One can speculate that this is linked to sex 
hormones and is embryo lethal, but the observation that females carry more pathogenic 
mutations than males should be taken with precaution. 
 
Figure 2.4. The frequency distribution of DHCR7 mutations. AFR, AMR, EAS, 
FIN, NFE, SAS and OTH represent African and African American, American, 
East Asian, Finnish, Non-Finnish European, South Asian and other populations, 
respectively. (A) The frequency distribution among different populations of the 
top 40 DHCR7 mutations of varying types occurring in more than 50 individuals 
archived in the ExAC database; (B) The frequency distribution among different 
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populations of pathogenic missense mutations chosen for this study; (C) The 
frequency distribution in males and females of the top 40 DHCR7 mutations of 
varying types occurring in more than 50 individuals archived in the ExAC 
database; (D) The frequency distribution in males and females of pathogenic 
missense mutations chosen for this study. 
3. Materials and Methods 
3.1. Selection of DHCR7 Missense Variants 
The missense mutations investigated in this work were selected using ClinVar [32] 
and ExAC [33] databases. The ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) 
was queried using the search term “DHCR7”. The results were further refined by 
missense mutations consisting of benign (2), likely benign (3), uncertain significance 
(30), likely pathogenic (15), pathogenic (26) and conflicting reports of pathogenicity (3) 
(as of 13 November 2017). The ExAC (Exome Aggregation Consortium) Browser 
(http://exac.broadinstitute.org/) was queried using the search term “DHCR7” and the 
entries were sorted by allele frequencies in descending order. The missense variants with 
an allele frequency greater than 0.00001, which were also classified in ClinVar were 
chosen for further in silico analysis. Of the chosen mutations, the variants defined as 
pathogenic or likely pathogenic in Clinvar database are classified as pathogenic 
mutations in this study while the others defined as uncertain significance in Clinvar 
database are classified as mutations with unknown effects. E288K and G303R are 
previously reported SLOS-causing mutations [34,35] although they are not classified as 
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pathogenic in the Clinvar database. Thus, E288K and G303R were treated as pathogenic 
mutations in this study. Overall, 16 pathogenic mutations and 18 mutations with 
unknown effects are classified for this study. 
3.2. Selection of Non-Pathogenic DHCR7 Mutations 
We first obtained the missense mutations in DHCR7 gene from the ExAC database 
[33], including the whole genome sequencing data from 60,706 unrelated individuals. In 
total, 280 missense mutations in DHCR7 were identified. The ExAC database also 
provides the corresponding allele frequency data from the 1000 Genomes Project and the 
NHLBI-GO Exome Sequencing Project (ESP) for each mutation. Individuals 
participating in the 1000 Genomes Project were all healthy while the objective of the ESP 
is discovery of novel genes and mechanisms contributing to heart, lung and blood 
disorders. As our goal was to select non-pathogenic mutations from the ExAC database, 
we applied the following selection criteria: (a) mutations with allele frequency >0 in the 
1000 Genomes Project; (b) mutations with allele frequency of 0 in the ESP. Thus, we 
classified the mutations identified from the healthy population of 1000 Genomes Project 
but not from the ESP as non-pathogenic mutations in this study. In total, 23 non-
pathogenic missense mutations were identified. 
3.3. Obtaining Allele Frequency and Gender Occurrence 
The allele frequency and gender data of DHCR7 mutations were obtained from 
EXAC database [33]. The most recent database version was downloaded from the FTP 
site (http://exac.broadinstitute.org/downloads) and mutations affecting the DHCR7 
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protein as well as their corresponding allele frequencies and gender data were obtained. 
The frequency of mutation by gender is calculated by the number of carrier females or 
males divided by the total number of carrier individuals. 
3.4. Generation of the 3D Model for DHCR7 
The 3D structure of the DHCR7 protein was generated by homology modeling due to 
lack of an existing experimental structure. Structure of the integral membrane sterol 
reductase from Methylomicrobium alcaliphilum (PDB: 4QUV) [19] was used as a 
template and subjected to MODELLER [36] for homology modeling. The sequence 
identity between the template and DHCR7 is 37% (sequence alignment is shown in 
Figure S3) and thus high structural similarity was observed between the generated model 
and template. The model with lowest DOPE score was selected for this study and further 
subjected to automatic loop refinement with MODELLER [36]. 
3.5. Property Distance (PD) 
To quantify the physical-chemical property differences between the wild type and 
mutant residues, we used the property distance (PD) as a parameter to quantitatively 
describe such changes. In this study, we describe physical-chemical properties of a 
particular residue using a property vector which includes two elements: hydrophobicity 
and charge. The hydrophobicity of the residues are taken from an experimentally 
determined hydrophobicity scale [37,38]. R and K carry +1 charges while E and D have 
−1 charges. All other residues are considered neutral. PD represents the Euclidean 
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distance of the property vector between the wild type and mutant residues (shown in 
Equation (1)). The PD between all types of residues are shown as a matrix in Figure 2.5. 
 (1) 
where x and y represent two types of residues; H and Q are corresponding hydrophobicity 
and charge for a particular residue. 
 
Figure 2.5. Property distance for all types of amino acid pairs. 
3.6. Evolutionary Conservation Score (EC Score) Calculation 
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The DHCR7 sequence from 35 different species were collected from UnitProt [39] 
and subjected to multiple sequence alignment with the T-Coffee webserver [40]. The EC 
score of each residue in the human DHCR7 sequence was calculated using the multiple 
sequence alignment with the following equation: 
 
(2) 
where  is the number of the species sharing identical residues in position i of 
the human DHCR7 sequence and  is the total number of the species in the 
multiple sequence alignment. 
3.7. Folding Free Energy Change (ΔΔG) and Relative Solvent Accessible Surface Area 
(rSASA) Calculation 
Several webservers were used to predict the effect of mutations on protein stability 
(folding free energy change (∆∆G)) using the generated homology model of DHCR7 
protein. The webservers used in this study include DUET [41], Eris [42], mCSM [43], 
SDM [44], Foldx [45] and SAAFEC [46]. The SASA were calculated using VMD [47]. 
As DHCR7 is a transmembrane protein, the membrane was also included when 
calculating the SASA. Thus, only the amino acids exposed to water were treated as 
exposed and the transmembrane regions were treated as buried in the calculation. The 
rSASA for residues were calculated using the following equation: 
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(3) 
where SASA(i) is the SASA measured for particular residue i and  is the 
maximum SASA obtained for a free residue (entire residue taken off the protein).  
3.8. Molecular Dynamic Simulations 
The membrane-protein-ligand system was built primarily using the CHARMM-GUI 
[48] tools. The DHCR7 protein with ligand structure was obtained from previous 
homology modeling. Ten mutant (V134L, T154R, R228Q, R260Q, E288K, T289I, 
F361L, G303R, R404C and A452T) structures were derived from the wild type DHCR7 
protein structure using VMD 1.9.3 [47] mutator package. The protein was embedded in a 
POPC bilayer using the CHARMM-GUI website. The protein was oriented to align with 
4QUV structure in the OPM [49] database. When the oriented protein was placed into the 
membrane, the z axis of the protein matched the z axis of the membrane. The whole 
system was solvated with 0.15 M KCl. The final system was 89.13 × 89.13 × 96.64 Å3 
with a total of about 70,800 atoms. 
Molecular dynamic simulation (MDS) was performed using NAMD2.11 [50]. The 
system first underwent energy minimization for 10 ps, then equilibrated through 6 cycles 
where harmonic constraints were applied to keep original positions of: (a) lipid head 
groups (force constants were gradually reduced from 5 kcal∙mol−1∙Å−2 to 0 
kcal∙mol−1∙Å−2), (b) protein backbone (force constants were gradually reduced from 10 
kcal∙mol−1∙Å−2 to 0 kcal∙mol−1∙Å−2), and (c) protein sidechains (force constants were 
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gradually reduced from 5 kcal∙mol−1∙Å−2 to 0 kcal∙mol−1∙Å−2). In addition, dihedral 
restraints were applied to keep cis double bonds and c2 chirality (force constants were 
gradually reduced from 500 kcal∙mol−1∙Å−2 to 0 kcal∙mol−1∙Å−2). A 1 fs timestep was used 
in the first few cycles and then switched to 2 fs for wild type whereas much smaller 
timesteps such as 0.01 fs were used for mutants to prevent restraints from failing. In the 
first two cycles, NVT simulation was performed and then switched to NPT simulation in 
the later cycles. Temperature was held at 303.15 K using a Langevin thermostat with a 
damping coefficient of 10 ps−1 and velocity rescaling thermostat. The pressure was 
maintained at 1 atm using a Langevin piston barostat with an oscillation period of 50 fs 
and a damping time constant of 25 fs. Electrostatic interactions between charged atoms 
were calculated using the particle mesh Ewald method. Van der Waals interactions were 
truncated at 12 Å with a switching function applied from 10 Å. RATTLE is used to 
constrain the length of all bonds involving a hydrogen atom. This stage of equilibration 
lasts for tens of ps to hundreds of ps. Then three 10 ns equilibration and 10 ns production 
runs with no constraints were performed for the wild type and each mutant. A 2 fs 
timestep was used. No velocity rescaling thermostat was used. Other conditions are the 
same as the previous stage. RMSD and root mean square fluctuation (RMSF) with the 
structure at the beginning of the 10 ns run as the reference structure were calculated using 
VMD 1.9.3. 
3.9. MM/PBSA Analysis 
To estimate the binding affinity of the DHCR7 protein with the ligand NADPH, we 
calculated the binding free energy using the MM/PBSA approach. For this purpose, we 
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performed three independent 20 ns MD simulations as described above. We took the 
frames with an interval of 20 ps from the last 10 ns and a total of 500 frames were 
selected from each trajectory. All ions, water and lipids were removed before MM/PBSA 
energy calculations. All the energy terms were averaged over 500 frames for each 
trajectory and the mean and standard deviation of binding free energy were calculated for 
wild type and mutant structures. The internal energy and van der Waals interactions were 
calculated using NAMD2.11b [50] by subjecting the structure to a one step equilibration 
at 300 K using dielectric constant = 2 for protein and = 80 for solvent. The electrostatic 
components of the binding free energy (Coulombic and solvation energy) were calculated 
by solving the Poisson Boltzmann (PB) equation using the Delphi program [51] with 
dielectric constant = 2 for protein and = 80 for solvent. The solvent accessible surface 
area (SASA) was calculated by VMD [47] with the solvent and lipid. The non-polar 
component of the solvation was further calculated with the following widely-used 
equation: 
 (4) 
where α = 0.0054 and β = 0.92 kcal/mol. 
3.10. K-Nearest Neighbors (KNN) classIfication 
K-Nearest Neighbors algorithm was used to classify the missense mutations with 
unknown effects in DHCR7 protein. The dataset includes 16 pathogenic missense 
mutations and 23 non-pathogenic missense mutations (non-classified/unknown effect 
mutations were excluded). The dataset was randomly partitioned into a training dataset 
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(29 mutations) and a testing dataset (10 mutations). The KNN classification was 
performed using R program and various numbers of K values were tested to obtain the 
best performance. 
4. Conclusions 
We investigated the effects of mutations causing SLOS on the biophysical 
characteristics of DHCR7 protein with the goal of identifying methods allowing the 
discrimination of pathogenic mutations from non-pathogenic mutations. We found that 
pathogenic mutations are located either within the transmembrane region or are near the 
ligand-binding site and are highly conserved between species. In contrast, non-pathogenic 
mutations observed in the general population are located outside the transmembrane 
region and have different effects on the conformational dynamics of DHCR7. Our 
analyses confirmed the inability of folding free energy modeling to deliver reliable results 
and to be used to discriminate pathogenic from non-pathogenic mutations in membrane 
proteins. Future investigations may include modeling the effects of DHCR7 mutations on 
melting temperature (Tm) via MD simulations conducted at different temperatures using 
the methodology adopted from recent work on NBD1 domain [52]. As mentioned in the 
work of Estacio et al. [52], the decrease of Tm may cause the protein to adopt partially 
misfolded states that become targeted for degradation. 
In this work, using three characteristics: solvent exposure of the mutation site, 
residue conservation and physico-chemical descriptors, we were able to distinguish 
between pathogenic and non-pathogenic mutations. This observation, along with 
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extensive MD simulations and MM/PBSA modeling, was used to classify R228Q as a 
pathogenic mutation. 
Taken together, these observations suggest that the non-classified mutation R228Q is 
in fact pathogenic. The analyses performed indicate that pathogenic effects may be of 
different origin, from affecting protein stability and dynamics to altering binding affinity 
and flexibility of the binding site.  
Supplementary Materials: Supplementary materials can be found at 
http://www.mdpi.com/1422-0067/18/ 
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Abbreviations 
SLOS Smith-Lemli-Opitz syndrome 
DHCR7 7-dehydroxycholesterol reductase 
ER Endoplasmic reticulum  
ExAC Exome Aggregation Consortium 
PD Property distance 
ECS Evolutional conservation score 
RMSD Root mean square deviation 
RMSF Root mean square fluctuation 
SASA Solvent accessible surface area 
rSASA Relative solvent accessible surface area 
KNN K-Nearest Neighbors 
MD Molecules dynamics 
CL Cytosol loops 
TM Transmembrane domain 
ESP Exome Sequencing Project 
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Abstract 
Autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, 
psoriasis, and multiple sclerosis have been linked to T helper 17 (Th17) cells and their 
cytokine, interleukin 17 (IL-17). Produced primarily by lymphocytes and acting on innate 
cells, IL-17 acts as a bridge between adaptive and innate immune responses. Th17 cells 
and IL-17 have been identified for their role in the pathogenesis of chronic inflammatory 
endometriosis. This narrative review will discuss the incidence, etiology and 
pathogenesis of endometriosis. It explores how immune cells involved with 
endometriosis produce IL-17, working with other cytokines to prolong the inflammatory 
response by stabilizing their messenger ribonucleic acid (mRNA) transcripts. The role of 
IL-17 to initiate the transcription of inflammatory factors through the nuclear factor-
kappa B (NF-κB), mitogen-activated protein kinase (MAPK) and CCAAT/Enhancer-
binding protein (C/EBP) pathways will be examined. Finally, this review will discuss 
current diagnosis and treatment of endometriosis, as well as future individualized 
treatment for women with endometriosis based on elevated IL-17 levels that target the 
IL-17 pathway. 
 
Keywords: Endometriosis, interleukin 17, inflammation 
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Introduction 
Endometriosis is an estradiol (E2)-dominant disease; the primary treatments 
currently consist of E2 inhibition, pain management with non-steroidal anti-inflammatory 
drugs (NSAIDS), and surgical interventions that include laparoscopic removal of 
abdominal lesions and adhesions (Greene et al., 2016; Hickey, Ballard, & Farquhar, 
2014). Recently, interleukin 17 (IL-17) emerged as a potential negative mediator of 
inflammation in endometriosis, thus presenting as a target for novel therapies. The two-
fold purpose of this narrative review is to explore literature targeting the role of IL-17 in 
the pathogenesis of endometriosis and to identify it as a target for potential new 
treatments for women experiencing this disease.  
Endometriosis affects 176 million women globally (Lessey & Young, 2014).  As 
a chronic and progressive inflammatory disorder, endometriosis is characterized by the 
growth of endometrial tissue outside of the uterus, typically in the pelvic cavity (ovaries, 
uterosacral ligaments, peritoneum, Pouch of Douglas and rectovaginal septum). These 
endometrial tissues, also called ectopic lesions, may grow in any place in the human 
body; even the lungs, brain and skin. The cells of these lesions proliferate and spread as 
they respond to cyclic hormonal signals, resulting in dysmenorrhea, inflammation, pelvic 
pain, and painful sexual intercourse. Symptoms of pleural endometriosis may include 
isolated chest pain, hemothorax and pneumothorax (Visouli et al., 2012). Additionally, 
women with this condition may also experience menstrual abnormalities and infertility 
(Hickey et al., 2014; Mahutte & Arici, 2002). While links between endometriosis and 
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infertility are not well-researched, approximately 25-50% of women with unexplained 
infertility also have endometriosis (Bulletti, Coccia, Battistoni, & Borini, 2010).  
Etiology and Pathogenesis of Endometriosis 
Endometriosis is thought to develop via retrograde menstruation, a phenomenon 
in which high intrauterine pressure or uterine contractions force menstrual debris 
containing endometrial cells, out of the fallopian tubes and into the peritoneum 
(Vercellini, Viganò, Somigliana, & Fedele, 2014). Although many women experience 
this event, only 10% of women with retrograde menstruation display the signs and 
symptoms of  endometriosis (Ahn, Monsanto, et al., 2015; Viganò, Parazzini, 
Somigliana, & Vercellini, 2004). Women with endometriosis may also exhibit genetic 
and immunological abnormalities predisposing them to disease development (Figure 3.1. 
Endometriosis pathogenesis) (Ahn, Monsanto, et al., 2015). 
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Figure 3.1. Endometriosis Pathogenesis 
 
Figure 3.1. Endometriosis due to combination of retrograde menstruation, genetic 
abnormalities in endometrial tissue and immune dysfunction. Abnormal immune cells 
produce pro-inflammatory proteins that support their survival, growth and spread. Author 
derived. 
Ectopic lesions consist of pseudo-endometrial tissues (stromal and glandular 
epithelial cells) permeated by dense vascular networks and surrounded by immune cells 
such as T lymphocytes, macrophages, and neutrophils (Ahn, Monsanto, et al., 2015; 
Nisolle, Casanas-Roux, Anaf, Mine, & Donnez, 1993). Additionally, ectopic lesion sites 
contain decreased levels of dendritic cells and natural killer cells compared to women 
without endometriosis (Tariverdian et al., 2009). The normal immunological response to 
cells in foreign locales consists of the initiation of acute inflammatory processes, 
coordination of the destruction of the ectopic cells, followed by resolution of 
inflammation. The combination of genetic abnormalities and immune dysfunction present 
in women at risk for endometriosis results in local immune cells supporting the lesions’ 
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survival and growth by decreasing their cytotoxic activities and inducing a state of 
chronic inflammation through the production of interleukins and other pro-inflammatory 
cytokines (Ahn, Monsanto, et al., 2015). Both lesions and immune cells, primarily 
macrophages, produce matrix metalloproteinases which degrade the basement membrane 
and adhesion molecules permitting the anchorage of lesions to peritoneal structures. 
Additionally produced are angiogenic growth factors that allow lesions access to oxygen 
and nutrients via blood vessel formation, growth factors that allow for the survival and 
proliferation of ectopic tissues, and chemotactic molecules which draw additional 
immune cells to the site (Bacci et al., 2009; Tariverdian et al., 2009).  
The presence of the macrophage-secreted cytokines tumor necrosis factor-alpha 
(TNF-α) and interleukin 1 beta (IL-1β) in the peritoneum induce refluxed endometrial 
stromal cells and peritoneal macrophages to overexpress cyclooxygenase-2 (COX-2), the 
rate-limiting enzyme involved in prostaglandin E2 (PGE2) synthesis. PGE2 is a critical 
factor regulating disease establishment and progression with levels of PGE2 higher in the 
peritoneal fluid of women with endometriosis than in healthy women (Wu et al., 2002). 
PGE2 first suppresses the phagocytic activities of macrophages and prompts them to 
secrete factors favorable for disease promotion, including IL-6 and transforming growth 
factor-beta (TGF-β) (Wu, Lu, Chuang, & Tsai, 2010). Additionally, PGE2 induces the 
production of angiogenic factors such as vascular endothelial growth factor (VEGF) and 
IL-8, stimulating the proliferation and migration of endothelial cells towards endometrial 
tissues to develop a vascular system in order to provide oxygen and nutrients (Wu et al., 
2010). Finally, endometriosis progression is highly E2-reliant, with the stimulation of 
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endometrial cells by PGE2 to independently manufacture their own E2.  This process 
promotes the production of growth factors involved in cell proliferation and survival. IL-
17, produced at ectopic lesion sites, promotes inflammation and draws additional immune 
cells to the area by direct induction of the expression of factors involved in 
endometriosis, including TNF-α, IL-1β, COX-2 and PGE2, IL-6, IL-8.  Additionally, IL-
17 indirectly enhances the actions of TNF-α and IL-1β by stabilizing their gene 
transcripts (Ahn, Monsanto, et al., 2015; Bacci et al., 2009; Hirata et al., 2008, 2011).   
Interleukin 17 (IL-17) 
IL-17, a relatively newly discovered member of the cytokine family (Rouvier, 
Luciani, & Mattei, 1993), exists as six isoforms. These isoforms, IL-17A-F, are 
connected to the development of numerous autoimmune and chronic inflammatory 
conditions, such as psoriasis, rheumatoid arthritis and irritable bowel disease (Chen & 
Kolls, 2017). The chief immunity roles of IL-17 and its primary cellular source, clusters 
of differentiation 4 (CD4) + T helper 17 (Th17) cells, are to maintain mucosal defenses 
and to direct immune responses against extracellular bacteria such as Klebsiella 
pneumoniae, Staphylococcus areus, and fungi such as Candida albicans (Li, Casanova, 
& Puel, 2017).  More recently, Th17 cells and IL-17 have been implicated in the 
pathogenesis of endometriosis. Zhang, et al. (2005) were the first to report an association 
between IL-17 peritoneal fluid concentration and the level of disease severity in 
endometriosis. Patients with mild or minimal endometriosis, particularly those with 
unexplained infertility, possessed significantly higher levels of IL-17 in the peritoneal 
fluid compared with more severe endometriosis cases (P=0.036) (Zhang, Xu, Lin, Qian, 
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& Deng, 2005). The authors concluded that IL-17 was essential for early disease 
development, inducing the production of inflammatory mediators such as IL-6, TNF-α, 
IL-1β, COX-2, and PGE2, all of which promote chronic inflammation and local E2 
production. Additionally produced are matrix metalloproteinase 3 (MMP3) and 
intercellular adhesion molecule 1 (ICAM1) (Albanesi, Cavani, & Girolomoni, 1999; 
Zhang et al., 2005). Subsequently, Ahn, Edwards, et al. (2015) determined that removal 
of ectopic endometrial lesions resulted in a decrease in levels of IL-17 (Ahn, Edwards, et 
al., 2015). 
Various immune cells involved in endometriosis produce IL-17, including activated 
Th17 cells, cytotoxic T-17 (Tc17) cells, gamma-delta T (γδT) cells, natural killer (NK) 
cells, neutrophils, and mast cells. Additionally, IL-17 targets gene expression in 
numerous cell types including those implicated in endometriosis, such as epithelial and 
endothelial cells, stromal cells, myeloid cells and immune cells (Cua & Tato, 2010; Eberl 
et al., 2004; Hueber et al., 2010; Kisielow, Kopf, & Karjalainen, 2008; Takatori et al., 
2009; Taylor, Roy, Jr, Sun, & Howell, 2014). Acting through the heterodimeric IL-17 
receptor (IL-17R) complex, IL-17 induces the production of factors related to the 
development and progression of endometriosis. These include: angiogenic factors such as 
VEGF and IL-8, which promote access to the local blood supply early in the disease 
process, intracellular adhesion molecules such as ICAM1, which allows endometrial cells 
to penetrate and grow on other tissues, and factors such as COX-2 and PGE2, which 
facilitate local E2 production. E2 initiates expression of factors required for the survival 
and proliferation of cells, as well as stimulating its own production via upregulation of 
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COX-2 by lesions, to perpetuate an unending cycle of inflammation (Gupta, Agarwal, 
Sekhon, & Krajcir, 2006). IL-17 has also been shown to also upregulate the production of 
IL-8 and COX-2 in endometrial stromal cells (Hirata et al., 2008, 2011). Due to their 
angiogenic, chemotactic and E2-producing capacities, both factors are highly implicated 
in the progression of endometriosis (Harada, Iwabe, & Terakawa, 2001; Ota, Igarashi, 
Sasaki, & Tanaka, 2001). Finally, treatment of endometrial carcinoma cells and human 
umbilical vein endothelial cells (HUVECs) with IL-17 revealed an increased production 
of angiogenic (VEGF, IL-8), pro-inflammatory (IL-1β, IL-6) and chemotactic 
(granulocyte-colony stimulating factor (G-CSF), C-X-C chemokine ligand 1 (CXCL1), 
CXCL12, CX3CL1, IL-8) factors (Ahn, Edwards, et al., 2015). 
 IL-17 modestly activates the production of IL-17-responsive inflammatory genes 
through the nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK) 
and CCAAT/Enhancer-binding protein (C/EBP) signaling pathways. More importantly, 
IL-17 works in tandem with other cytokines to stabilize messenger RNA (mRNA) and 
increase the lifespan of inflammatory transcripts (Figure 3.2). Upon IL-17 binding to the 
extracellular portion of IL-17R, the ubiquitin ligase adaptor protein NF-κB activator 1 
(ACT1), which is required for activation of all IL-17 signal transduction pathways, 
moves to the intracellular portion of IL-17R where it attracts and ubiquinates tumor 
necrosis factor receptor-associated factor (TRAF) proteins. (Chang et al., 2006; Liu et al., 
2009; Novatchkova et al., 2003). Activation of TRAF6 (Figure 3.2) results in the 
activation of the NF-κB, MAPK and C/EBP pathways and transcription of pro-
inflammatory genes that code for various interleukins and other cytokines (IL-1β, IL-6, 
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TNF-α), chemokines (IL-8, G-CSF, CXCL1), and other factors, including pro-angiogenic 
VEGF and pro-estrogenic COX-2 and PGE2 (Table 1).  
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Figure 3.2. IL-17 Signaling 
 
Figure 3.2. Binding of IL-17 to IL-17 receptor complex results in 1) the expression of 
pro-inflammatory cytokines such as IL-1β via the NF-κbB, C/EBP and MAPK pathways, 
or, 2) stabilizes the mRNA of other cytokines such as IL-1β or TNF-α by preventing the 
decay of their mRNA transcripts. Adapted with permission from: (Amatya, Garg, & 
Gaffen, 2017). 
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Table 3.1: Inflammatory Factors Involved in Disease Progression Associated with IL-17 
or Th17 Activities 
Cytokines Angiogenic 
factors 
Adhesion 
molecules 
Chemokines E2-
production 
factors 
TNF-α VEGF ICAM1 IL-8 COX-2 
IL-1β IL-8 VCAM1 G-CSF PGE2 
TGF-β   CXCL1  
IL-6   CXCL12  
IL-21   CX3CL1  
IL-22   CCR6  
IL-23   CCL20  
GM-CSF     
Note: TNF-α= tumor necrosis factor alpha; IL-1β= interleukin 1 beta ; TGF-β= tumor 
growth factor beta; IL-6= interleukin 6; IL-21= interleukin 21; IL-22=interleukin 22; IL-
23=interleukin 23; GM-CSF= granulocyte-macrophage colony-stimulating factor; 
VEGF=vascular endothelial growth factor; IL-8=interleukin 8; ICAM1=intracellular 
adhesion molecule 1; VCAM1= vascular cell adhesion molecule 1;G-CSF= granulocyte-
colony stimulating factor; CXCL1= chemokine (C-X-C motif) ligand 1; CXCL12= C-X-
C motif chemokine 12; CX3CL1= chemokine (C-X3-C motif) ligand 1; CCR6= C-C 
motif chemokine receptor 6; CCL20= C-C motif chemokine ligand 20; COX-
2=cyclooxygenase 2; PGE2= prostaglandin E2.  
 
IL-17-mediated inflammation appears to be more potent when acting in concert with 
other cytokines, such as TNF-α, IL-1β, IL-22 and interferon gamma (IFN-γ) (Beringer, 
Thiam, Molle, Bartosch, & Miossec, 2017; Chabaud, Fossiez, Taupin, & Miossec, 1998; 
Gaffen, Jain, Garg, & Cua, 2014; Liang et al., 2006; van Nieuwenhuijze et al., 2014). The 
cooperation between IL-17 and TNF-α results in the stabilization of previously unstable 
TNF-α mRNA transcripts by preventing decay (Hartupee, Liu, Novotny, Li, & Hamilton, 
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2007; Karlsen, Borregaard, & Cowland, 2010; Miossec, 2003; Shen & Gaffen, 2008). In 
this process, the presence of IL-1 or TNF signaling results in the phosphorylation of 
ACT1, shifting priority from TRAF6 activation to TRAF2/5 activation by blocking 
TRAF6 binding. The ACT1/TRAF2/TRAF5 complex removes the pre-mRNA-splicing 
factor 2 (SF2) from the 3’ untranslated region (UTR) of mRNA transcripts and recruits 
the mRNA stability factor human antigen R (HuR) to compete with SF2 for mRNA 
binding sites, thus preventing SF2-mediated RNA decay, while promoting transcript 
stability and translational efficacy. These processes lead to increased levels of mRNA 
transcripts of pro-inflammatory cytokines which are beneficial during an acute 
inflammatory response (such as an infection). However, without the need for active 
pathogen clearance or wound healing, this process may promote chronic inflammation 
present in such diseases as endometriosis. Indeed, Hirata et al. (2008; 2011) found that 
IL-17 acts synergistically with TNF-α to increase expression of pro-inflammatory factors 
such as COX-2 and IL-8 by endometrial stromal cells (Hirata et al., 2008, 2011). IL-17 
treatment alone produced moderate increases in these factors, but the combination of 
TNF-α and IL-17 greatly increased levels.  
T helper 17 Cells Produce IL-17  
Several cell types have been shown to produce IL-17, but Th17 cells, identified in 
2005, (Harrington et al., 2005; Park et al., 2005) are the primary source of IL-17 
production. T helper cells are a subset of T lymphocytes, which support the immune 
response through the secretion of cytokines and chemokines to recruit and activate 
additional immune cells. There are several types of T helper cells (Th1, Th2, Th17, T 
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regulatory) each with distinct roles in immunity, from coordinating immune responses 
against pathogen-infected cells to dampening ongoing immune reactions. The normal 
functions of Th17 cells are to: 1) drive immunological reactions against extracellular 
bacteria and fungi, 2) produce anti-microbial compounds, attract neutrophils, and 3) 
maintain mucosal barrier immunity (Kolls & Khader, 2011; Stockinger, Veldhoen, & 
Martin, 2007; Ye et al., 2001). A combination of TGF-β plus IL-6 stimulation results in 
Th17 cell development, though other cytokines such as IL-1β and IL-13 may enhance the 
activation. Th17 cells (Figure 3.3. Development of IL-17-producing Th17 cells) are 
characterized by the expression of the transcription factor retinoic acid receptor-related 
orphan receptor gamma t (RORγt) and the production of IL-17, though other cytokines, 
including IL-21, IL-22, IL-6, TNF-α and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) may also be secreted by Th17 cells (Gaffen, 2009). 
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Figure 3.3. Development of IL-17-Producing Th17 Cells 
 
Figure 3.3. Stimulation by TGF-β and IL-6 active STAT3 and promote expression of 
Th17 master transcription factor RORγt. IL-23 secretion promotes disease-causing 
phenotype. Th17 cells may produce additional cytokines, including IL-6. Innate immune 
cells in endometriosis may produce IL-17. IL-17 binds IL-17 receptor complex on target 
cells, causing production of pro-inflammatory mediators. Author derived. 
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Th17 cells, while extensively linked to several autoimmune conditions, such as 
psoriasis (Martin et al., 2013), rheumatoid arthritis (Sarkar, 2010) and inflammatory 
bowel disease (Fujino et al., 2003), have not been widely investigated in relationship to 
endometriosis. The presence of Th17 cells at the sites of ectopic lesions was first reported 
in 2008 (Hirata et al., 2008). In another study, Hirata et al, 2010, corroborated the 
involvement of Th17 cells in endometriosis by reporting that Th17 lymphocytes near 
ectopic lesions express C-C chemokine receptor 6 (CCR6) while the ectopic lesions 
secret its ligand, the Th17 chemoattractant molecule C-C chemokine ligand 20 (CCL20), 
indicating that CCL20/CCR6 signaling is involved in drawing Th17 cells to ectopic 
lesions to further disease progression (Hirata et al., 2010).  
A recent study comparing CD4+ T helper cell subsets in the blood, endometrium, 
and ectopic lesions of women with endometriosis found that T cell populations in lesions 
were skewed towards Th17 cells while endometria contained higher populations of Th1 
cells (Takamura et al., 2015). There was no significant difference in Th2 (p = 0.29) or T 
regulatory (p = 0.67) cells between lesions and eutopic endometria. However, there were 
significantly more Th1 (P=0.041) cells in the blood of women with endometriosis 
compared to those without endometriosis, indicating a difference in inflammatory 
microenvironments both locally and systemically. Similarly, Gogacz, et al. (2016) 
reported that patients with severe endometriosis possessed a higher level of IL-17-
producing Th17 cells in the peritoneal fluid than women with mild or minimal 
endometriosis (Gogacz et al., 2016).   
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Other researchers profiled cytokines and T helper cell subsets in the peritoneal fluid 
of women with varying stages of endometriosis and also found that, as previously 
reported, levels of IL-17, IL-6 and TGF-β as well as Th17 cells were elevated (Chang et 
al., 2017). Interestingly, in the more advanced cases of the disease, there were more anti-
inflammatory cytokine-producing populations of Th17 cells, including IL-10 and IL-4. 
This indicates that as the disease progresses, the local environment begins a switch from 
pro-inflammatory-dominance to a balance between pro-and anti-inflammatory factors in 
later stages of disease progression. Thus, it appears that IL-17 promotes endometrial 
stromal cell angiogenesis, proliferation, and a pro-inflammatory environment while 
inhibiting adhesion in order to enhance the rapid spread of the disease throughout the 
tissues (Ahn, Edwards, et al., 2015; Chang et al., 2017). The suppressive effects of IL-10 
on IL-17 in more advanced cases of endometriosis appears to result in an increase of 
lesion adhesions in ectopic sites, as well as deeper infiltration of endometriosis into 
affected tissues (Chang et al., 2017). 
The ultimate determinant of whether Th17 cells will be involved in endometriosis 
appears to be attributed to local cytokines present during activation, particularly IL-23 
(Aggarwal, Ghilardi, Xie, de Sauvage, & Gurney, 2003; Cua et al., 2003; Langrish et al., 
2005). Andreoli et al. (2011) found elevated levels of IL-23, implicated in the 
development of pathogenic Th17 cells, in the peritoneal fluid of infertile patients with 
endometriosis (Andreoli et al., 2011). This suggests that IL-23 may also be an emerging 
factor in infertility in women with endometriosis although current research is limited at 
this time. 
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Current Diagnosis and Treatment of Endometriosis 
As noted previously there is a proliferation of endometrial lesions that spread as 
they respond to cyclic hormonal signals, resulting in dysmenorrhea, inflammation, pelvic 
pain, and painful sexual intercourse.  Menstrual abnormalities and infertility are also 
experienced by women with the diagnosis. (Hickey et al., 2014; Mahutte & Arici, 2002). 
While links between endometriosis and infertility are not well-researched, approximately 
25-50% of women with unexplained infertility also have endometriosis (Bulletti et al., 
2010).  
When women present with pelvic pain and other symptoms associated with 
endometriosis, healthcare professionals should conduct a family history and physical 
examination which includes a thorough gynecologic history and examination.  Tests to 
confirm differential diagnoses, such as nongynecological disorders causing pelvic pain 
(renal or urinary tract infections, irritable bowel syndrome, or sexually transmitted 
disease), may be indicated. Although ultrasound and other imaging modalities can detect 
the presence of endometrial lesions in women, definitive diagnosis of endometriosis is by 
histopathology, after laparoscopic or surgical removal of lesions (Armstrong, 2011).  
 While the patient with endometriosis is undergoing laparoscopy or surgery, the 
surgeon may elect to ablate, lyse or excise endometrial lesions. Surgical intervention may 
provide long-term pain relief, enable fertility, and/or delay surgically induced menopause 
via oophorectomy and hysterectomy (Journal of Obstetrics and Gynaecology Canada 
[JOGC], 2010).  Initial medical treatment of endometriosis includes the use of oral, 
injectable, and intrauterine progestins, combined oral contraceptives, gonadotropin-
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releasing hormone (GnRH) agonists, NSAIDs, and danazol. Since medical therapy with 
GnRH agonists may result in low E2 symptoms (insomnia, vaginal dryness, hot flashes, 
decreased libido and decreased bone mineral density), it is not unusual that low-dose 
hormone therapy and/or bisphosphonates and calcium supplementation is added to the 
medical treatment regimen (Armstong, 2011; JOCG, 2010).  
The Role of IL-17 in Developing Future Treatments for Endometriosis 
 Currently, clinical intervention trials recruiting study participants experiencing 
endometrial pain include drug trials using cabergoline (a dopamine receptor agonist) with 
norethindrone acetate, a botulinum toxin which blocks acetylcholine and the GnRH 
agonists, elagolix and relugolix (Taylor et al., 2017). Recently IL-17, more specifically 
IL-17A, a product of the clathrin light chain A 8 (CTLA8) gene, is a viable drug target for 
treating chronic inflammatory conditions (sporatic arthritis and ankylosing spondylitis) 
that result from excessive levels of IL-17 (Miossec, 2017). The first inhibitor of IL-17A, 
secukinumab, a human monoclonal antibody (anti-IL-17A), has the indication for the 
treatment of moderate-to-severe psoriasis. Ixekizumab is a monoclonal antibody that 
neutralizes the effects of IL-17.  Another monoclonal antibody that targets the IL-17A 
receptor, rather than the IL-17A cytokine, is broadalumab.  However, the long-term use 
of these monoclonal antibodies has not been researched.  Additionally, none of these 
drugs have been approved for treatment of other inflammatory disorders, including 
endometriosis (Campa, Mansouri, Warren & Menter, 2016; Wasilewska, Winiarska, 
Olsezewska & Rudnicka, 2016).  Other drug candidates on the horizon that target the IL-
17 pathway include anit-IL-17 nanoantibodies, dual anti-IL-17 and TNF- α inhibitors and 
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fynomers, engineered proteins that act as antibodies allowing for the production of bi-
specific anti-TNF and anti-IL-17 A antibodies (Campa et al., 2016; Miossec, 2017; 
Wasilewska et al., 2016).  
Conclusion 
The cytokine IL-17 has been implicated in the pathogenesis of endometriosis. IL-
17 directly regulates gene expression through the pro-inflammatory NF-κB, MAPK and 
C/EBP pathways and indirectly synergizes with other cytokines to stabilize and increase 
the lifespan of transient mRNA transcripts, thus prolonging an inflammatory response. 
IL-17 plays a role in perpetuating the cycle of E2-dominated inflammation at ectopic 
lesion sites, helping to create conditions suitable for the survival, growth and spread of 
these endometrial lesions to other parts of the body. Though primarily produced by Th17 
cells, other cell types may also produce IL-17, particularly in the early stages of the 
disease, before adaptive immune cells (such as Th17 lymphocytes) have time to become 
activated. IL-17 appears to be an important factor in earlier stages of endometriosis, 
before conditions shift towards a more anti-inflammatory milieu.  
IL-17 is a target for drug development that may reduce the inflammation and 
resultant pelvic pain experienced by women with endometriosis. Although many human 
monoclonal antibodies have been investigated and ultimately received approval to treat 
other inflammatory disorders, no monoclonal antibody is approved for the treatment of 
endometriosis.  Until they gain expanded approval, drugs and therapies that only treat 
symptoms are available to women suffering with endometriosis.  
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ASSESSMENT OF BETA-CARYOPHYLLENE (BCP) FOR THE TREATMENT OF 
ENDOMETRIOSIS USING AN IN VITRO APPROACH 
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Abstract 
Endometriosis is an estrogen-dominant inflammatory condition featuring 
abnormal cell proliferation, angiogenesis and avoidance of apoptosis. The blood and 
peritoneal fluid of women with endometriosis exhibit elevated levels of estradiol (E2) and 
other pro-inflammatory factors including the cytokines interleukin 6 (IL-6) and IL-17 and 
the angiogenic mediator vascular endothelial growth factor (VEGF). Beta-caryophyllene 
(BCP) is a phyto-cannabinoid which selectively binds the anti-inflammatory cannabinoid 
receptor 2 (CB2). The effects of BCP were examined on cell proliferation, viability and 
VEGF expression in a cell culture model. In addition, the expression of cannabinoid 
receptors CB1 and CB2 were examined in two endometrial cancer cell lines and in 
endometrial tissue samples. Reverse transcription polymerase chain reaction (rtPCR) 
analysis revealed that both Ishikawa and RL95-2 cell lines express CB1, but not CB2. 
Thus, these cell lines are unlikely to respond to BCP stimulation. Immunohistochemistry 
showed that CB2 expression is upregulated in endometriosis-positive endometrial tissue 
compared with healthy tissue. BCP decreases IL-17-induced VEGF production in 
endometriosis-positive endometrial stromal cells but not when IL-6 is present. These 
results suggest that BCP may be a useful treatment option for endometriosis. 
 
Keywords: Endometriosis, cannabinoids, cannabinoid receptor 1 (CB1) 
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Introduction 
Endometriosis is a common gynecological condition estimated to affect 10% of 
women of reproductive age (Bulun, 2009). It is characterized by the growth of 
endometrial-like tissue in extra-uterine locations which respond to cyclical hormones, 
particularly estradiol (E2), build up, and shed into the surrounding area. (Bulun, 2009). 
The resulting chronic inflammatory situation may cause fatigue, pelvic pain, abnormal 
menstruation, and infertility (Hickey, Ballard, & Farquhar, 2014; Mahutte & Arici, 
2002). Endometriosis occurs as the result of a combination of genetic, environmental and 
immunological factors (Berkkanoglu & Arici, 2003). Based on twin studies, 
endometriosis is estimated to be approximately 50% heritable (Saha et al., 2015). The 
remaining 50% results from environmental factors which may modify the epigenome. 
Increased DNA methylation of genes involved with endometriosis amelioration, such as 
progesterone receptor (PR) may occur (Kobayashi, Imanaka, Nakamura & Tsuji, 2014). 
Environmental risk factors include low birth rate, multiple pregnancies, childhood 
exposure to smoke and exposure to diethylstilbestrol in utero (Kvaskoff, Bijon, Clavel-
Chapelon, Mesrine & Boutron-Ruault, 2013; Missmer, Hankinson, Spiegelman, Barbieri, 
Michels & Hunter, 2004) 
Current treatments for endometriosis include estrogen-depleting therapies such as 
the gonadotropin-releasing hormone (GnRH) drug elagolix and oral contraceptives (H. S. 
Taylor et al., 2017). These therapies act to directly block ovulation or to simulate states in 
which ovulation does not occur, such as in pregnancy. Non-steroidal anti-inflammatory 
drugs (NSAIDs) are used to manage pain, and surgery may be performed to remove 
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ectopic growths (Greene et al., 2016; Hickey et al., 2014).  However, hormone treatments 
often have adverse side effects, e.g.; prevent ovulation and therefore, conception, with 
reduction in symptoms only during actual treatment (Greene et al., 2016). Surgery often 
fails to remove all lesions and may lead to adhesions, sterility and other complications 
(Vercellini, Viganò, Somigliana & Fedele, 2014). Thus, novel therapies with fewer side 
effects which allow for conception and pregnancy are needed.  
Beta-caryophyllene (BCP) is an essential oil present in Cannabis sativa 
(Hendricks et al., 1975) and commonly consumed spices, e.g. oregano, cinnamon and 
black pepper (Jayaprakasha,  Rao, & Sakariah, 2003; Mockute, Bernotiene, & 
Judzentiene, 2001; Orav, Stulova, Kailas, & Müürisepp, 2004).  BCP makes up 
approximately 35% of the essential oil present in cannabis (Hendricks et al., 1975). It 
selectively binds the G-protein-coupled cannabinoid receptor 2 (CB2), activating anti-
inflammatory effects without the characteristic psychotropic effects of cannabis use 
(Gertsch et al., 2008). As an FDA-approved food additive, BCP has not demonstrated 
genotoxic or cytotoxic effects (Molina-Jasso, Álvarez-González, & Madrigal-Bujaidar, 
2009). 
The anti-inflammatory properties of BCP have been documented.  Rodent model 
inflammatory diseases, such as colitis (Bento et al., 2011; Cho et al., 2015), edema 
(Fernandes et al., 2007), Alzheimer’s (Cheng et al., 2014) and type 2 diabetes (Basha & 
Sankaranarayanan, 2014, 2015) have been used to demonstrate the anti-inflammatory 
effects of BCP. Table 4.1 compares some anti-inflammatory effects of BCP on different 
diseases.   
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Table 4.1: Effects of BCP on Inflammatory Diseases 
Disease Effector Effect 
Colitis CB2 activation Reduces apoptosis, cell 
proliferation and cell 
migration (Bento et al. (2011) 
Multiple myeloma, breast and 
prostate cancer cells 
Suppression of signal 
Transducer and activator of 
transcription-3 (STAT3) 
 
Upregulation of inflammatory 
mediator including VEGF 
Prevents proliferation and 
induces apoptosis (C. Kim et 
al., 2014) 
 
Establishes circulatory 
system (C. Kim et al., 2014) 
Edema Downregulation of 
inflammatory mediators 
including TNF-α, PGE2 and 
COX-2 
Decreased inflammation, 
likely through inhibition of 
the NF-κB pathway 
(Fernandes et al., 2007) 
Alzheimer’s disease Downregulation of the 
inflammatory mediators 
TNF-α, IL-1β and COX-2 
Prevented cognitive 
impairment (Cheng, Dong & 
Lui, 2014) 
Note. CB2= cannabinoid receptor 2; VEGF= vascular endothelial growth factor; TNF-α= 
tumor necrosis factor alpha; PGE2= prostaglandin E2; COX-2=cyclooxygenase 2; IL-1β= 
interleukin 1 beta. 
 
The endocannabinoid system (ECS) is involved in a variety of essential 
physiological processes including: food intake (Soria-Gomez et al., 2014), metabolism 
(Mazier, Saucisse, Gatta-Cherifi & Cota, 2015), pain sensation (Woodhams, Sagar, 
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Burston & Chapman, 2015) cognition (Kruk-Slomka, Dzik, Budzynska & Biala, 2017) 
and inflammation (Crowe, Nass, Gabella & Kinsey, 2014). Endogenous cannabinoid 
ligands, their receptors, and their regulating enzymes make up the ECS (Ayakannu, 
Taylor, Willets, & Konje, 2015). Endocannabinoids primarily exert their effects through 
cannabinoid receptors CB1 and CB2 (Matsuda, Lolait, Brownstein, Young, & Bonner, 
1990; Munro, Thomas, & Abu-Shaar, 1993). In vivo, these receptors are activated by the 
binding of endocannabinoid ligands derived from arachidonic acid, primarily anandamide 
(AEA) and 2-arachidonoylglycerol (2-AG) (Devane et al., 1992; Sugiura et al., 1995). In 
the female reproductive system, expression of endocannabinoid ligands, their regulating 
enzymes and their receptors vary throughout the menstrual cycle, during implantation and 
during pregnancy (Battista, Bari, & Maccarrone, 2013). 
Activation of the CB1 receptor is attributed to the pathophysiological effects 
characteristic of Cannabis sativa use, and is also involved in cell proliferation, apoptosis, 
angiogenesis and inflammation (Dhopeshwarkar & Mackie, 2014; Maccarrone et al., 
2015). The CB1 receptor is primarily expressed in the brain, particularly in regions 
responsible for motor control, cognition and memory, and sensory perception (Gentilini 
et al., 2010; Kruk-Slomka et al., 2017; Morera-Herreras, Miguelez, Aristieta, Torrecilla, 
Ruiz-Ortega & Ugedo, 2016).  CB1 is also expressed peripherally in the eye, spleen, 
testis and the uterus, as endometriosis lesions are derived from endometrial tissues 
(Aloway, Kumar, Laun & Song, 2017; Cassano, Calcagnini, Pace, De Marco, Romano & 
Gaetani, 2017). CB2 receptors are primarily expressed by circulating cells of the immune 
system and immune organs (spleen and lymph nodes), as well as the intestines, lungs, 
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uterus, pancreas, and skin (Casanova et al., 2003; Gardner et al., 2002; Onaivi et al., 
2002; Pertwee, 1997). Activation of CB2 results in anti-inflammatory responses (Deng et 
al., 2015).  
Taylor et al. (2010) reported an intense CB1 expression in glandular epithelium 
when compared with stroma, but did not find this expression to be regulated throughout 
the menstrual cycle. This study also found that CB2 expression was low in the early 
stages of the menstrual cycle, but peaked in the late proliferative phase (2010). Resuehr et 
al. (2012) found an increased CB1 mRNA and protein expression in the secretory phase 
of the cycle, regulated by progesterone (Resuehr, Glore, Taylor, Bruner-Tran, & Osteen, 
2012). Resuehr et al. (2012) further demonstrated that CB1 mRNA and protein 
expression is significantly lower in the endometria of women with endometriosis 
compared to healthy controls and attributed this reduced expression to the progesterone 
resistance characteristic of endometriosis. This was corroborated by Sanchez et al. (2016) 
who found that CB1 expression was reduced in endometrial stromal cells (ESCs) in 
women with endometriosis compared to controls, and that this decreased expression 
contributes to disease-associated pain. Bilgic et al. (2017) and Sanchez et al. (2016) 
found that CB1 and CB2 proteins are decreased in endometriosis tissue compared to 
controls.  Iuvone et al. (2008) reported an upregulation of CB2 on mast cells in the 
endometria of women suffering from endometritis compared to the endometria of healthy 
women (Iuvone et al., 2008). While there is little data on the expression of 
endocannabinoid proteins in ectopic lesions, Leconte et al. (2010) found the presence of 
 
91 
 
CB1 and CB2 receptors on cells derived from endometriotic implants (Leconte et al., 
2010).  
Few studies have explored the effects of BCP in or on endometriosis. Abbas, 
Taha, Zihlif & Disi (2013) examined the effects of BCP on a rat model of surgically-
induced endometriosis with very promising results. Treatment with 10 mg/kg BCP 
resulted in a 50% decrease in endometriotic lesion surface area compared to controls. 
Furthermore, no difference in fertility between groups was observed, indicating that BCP 
has no negative impact on reproductive potential as is reported for many of the currently-
available treatments for endometriosis (Panay et al., 2008). These researchers also found 
BCP induced apoptosis in both endometrial luminal epithelial cells as well as in vascular 
endothelial cells. Chang et al. (2014) found that BCP extracted from Siegesbeckia 
orientalis exerted an anti-proliferative effect on human endometrial RL95-2 cells (Chang 
et al., 2014). 
The purpose of this experimental laboratory study was to characterize the 
presence of CB1 and CB2 receptors in two endometrial cancer cell lines and also in 
normal and endometriosis-positive endometrial tissues. In addition, the effects of 
treatment with BCP on cell proliferation, viability, estrogenicity and VEGF production in 
endometrial cancer cells and primary endometrial stromal cells were examined. 
Materials and Methods 
Ethics Approval for Human Samples 
Greenville Health Systems IRB: #38040, approved on 2/23/2015. Documents 
provided in Appendix A. 
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Human Endometrium Sample Collection 
Written informed consent was obtained from subjects prior to sample acquisition. 
Human endometrium samples were collected from two Caucasian women in their late 
20’s, one with endometriosis and one without endometriosis, at the time of surgery in the 
Greenville Health System. The presence or absence of endometriosis was confirmed 
during surgery. The woman without endometriosis was placed in the control group. 
Endometrial samples were collected by pipelle sampling and placed in isolation media 
consisting of Dulbecco’s Modified Eagles Medium (DMEM)/high glucose media 
(HyClone, Logan, UT) supplemented with 5% fetal bovine serum and 2% 
penicillin/streptomycin amphotericin B (Lonza, Walkersville, MD).  
Stromal Cell Isolation 
Endometrial samples were rinsed with Hank’s Balanced Salt Solution (Corning, 
Manassas, VA) and minced into 1-millimeter (mm) fragments with a sterile scalpel. 
Tissue fragments were incubated for 2.5 hours in a 1X collagenase/isolation media 
solution with rapid shaking on an orbital shaking platform. Digested tissue was forced 
through a stacked sterile wire sieve assembly with number 100 wire cloth sieve (140 μm 
size, Newark Wire Co., Newark, NJ), followed by a number 400 wire cloth sieve (37 μm) 
to isolate the stromal cells from the epithelium. The stromal cell-containing fluid was 
collected in a 50 milliliter (mL) falcon tube and centrifuged at 500 g for 5 minutes, the 
supernatant was decanted and the pellet was resuspended in isolation media. Red blood 
cells were removed by gently layering the cell suspension from the pellet atop 3mL 
Ficoll-Paque (Pharmacia, Piscataway, NJ) in a 15 mL tube. The tube was centrifuged at 
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400 g for 10 minutes with the brake set to zero to separate the red blood cells from the 
stromal cells. The milky middle stromal cell layer was carefully pipetted off and re-
centrifuged at 500 g for 5 minutes. The supernatant was aspirated, and the pellet was 
resuspended in stromal media consisting of 1:1 Medium 199/F-12 Ham’s nutrient 
mixture (HyClone) media supplemented with 4% heat-inactivated fetal bovine serum, 1% 
penicillin/streptomycin and 1 ml ITS+ (insulin, human transferrin and selenous acid) 
Premix Universal Culture Supplement (Corning, Tewksbury, MA) per 1000 ml. The cell 
suspension was added to stromal media in flasks and maintained at 37 ℃ in a 5% CO2 
humidified atmosphere.  
Reagents and Cell Culture 
Ishikawa cells (CRL-2923; ATCC, Manassas, VA) and RL95-2 cells (CRL-1671; 
ATCC) were maintained in Dulbecco’s Modified Eagles Medium and Ham’s F-12 
nutrient mixture (DME/F-12) (1:1) (HyClone) supplemented with 10% heat-inactivated 
fetal bovine serum and 1% penicillin/streptomycin at 37 ℃ in a 5% CO2 humidified 
atmosphere. Prior to all experiments, Ishikawa and RL95-2 cells were grown for three 
days in hormone-free media consisting of DMEM/F-12 (1:1) (HyClone) without phenol 
red supplemented with 5% heat-inactivated charcoal-stripped fetal bovine serum (JR 
Scientific, Inc., Woodland, CA), 1% penicillin/streptomycin and 15 mM hydroxyethyl 
piperazineethanesulfonic (HEPES) free acid (HyClone) as a buffering agent. Endometrial 
stromal cells (ESCs) were also placed in hormone-free media with 2% heat-inactivated 
charcoal-stripped fetal bovine serum. 
Alkaline Phosphatase Assay 
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To screen for estrogenic activity, the alkaline phosphatase assay developed by 
Littlefield and colleagues (Littlefield, Gurpide, Markiewicz, McKinley, & Hochberg, 
1990) was performed using Ishikawa and RL95-2 cells. Cells were switched to hormone-
free medium (see above) three days prior to the experiments. The cells were washed with 
1× PBS, trypsinized until cells detached and then resuspended in medium. Approximately 
20,000 cells were added to each well with 200 μl medium and grown for 24 hours. The 
cells were then treated with medium containing specified concentrations of BCP diluted 
in ethanol (10-12, 10-11, 10-10, 10-9 and 10-8M), estradiol (E2) (10-8M) or the anti-estrogen 
ICI 182, 780 (10-6M) for 72 hours. The medium was changed daily.  
At the end of the treatment, the alkaline phosphatase assay was performed. Cells 
were washed twice with cold 1× PBS and the plates were frozen for 15 min at −140°C 
and then thawed to lyse the cell membranes. After thawing 50-μl of cold soluble substrate 
consisting of SigmaFast p-nitrophenyl phosphate tablets (Sigma, St. Loius, MO) 
dissolved in deionized H2O was added to each well on ice. The plates were incubated at 
room temperature on a plate shaker. Between 1-3 hours of incubation, the substrate 
solution produced a yellow color when alkaline phosphatase was present. The absorbance 
was read in a plate reader at 405 nanometers (nm) (Bio-Rad, Hercules, CA). 
CyQUANT Cell Proliferation Assay 
The effect of BCP stimulation on cell proliferation in Ishikawa and RL95-2 cells 
was measured using the CyQUANT Cell Proliferation Assay kit (C7026; Invitrogen, 
Eugene, OR). Cells were plated in triplicate on a 96-well plate at 5,000 cells/well (200µl 
volume/well) and treated with different concentrations of BCP diluted in ethanol with or 
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without estradiol (10-8M). Cells were incubated for 24, 48 or 72 hours at 37°C with 5% 
CO2. Treatment medium was changed at 48 hours.  Post-treatment, medium was gently 
shaken out of the wells and the plate was blotted on clean paper towels. Plates were 
frozen at -70℃ for a minimum of 24 hours. After thawing plates at room temperature, 
200 µL of the 1X dye solution from the CyQUANT Cell Proliferation Assay kit was 
added to each well and incubated at room temperature for 5 minutes, protected from 
ambient light. Colorimetric analysis was conducted using spectrophotometry with 
fluorescence set at 480 nm excitation and 520 nm emission. 
Trypan Blue Proliferation Assay 
 The effects of BCP stimulation on cell proliferation in ESCs derived from a 
patient with and one without endometriosis was measured using a trypan blue viability 
assay. ESCs were plated in triplicate at 50,000 cells/well in 6-well plates (1.5 mL 
volume/well). Cells were treated with BCP (10-8M) or control (media plus EtOH vehicle). 
Cell numbers were obtained after two, four and six days of treatment. Cells were 
detached from wells using trypsin, collected, centrifuged, supernatant aspirated, and the 
pellet was resuspended in media. The solution was diluted with trypan blue which passes 
through the cell membrane of dead and dying cells to stain the cytoplasm blue but is 
excluded from viable cells whose cytoplasm remains clear.  Viable cells from each 
replicate were counted using both chambers of a hemocytometer. The number of cells per 
mL was calculated using the formula: average number of cells counted * dilution factor * 
10,000 * volume of media added to pellet (mL). The average number of cells/mL was 
calculated. 
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Human VEGF ELISA 
 The effects of BCP stimulation on ESC production of human VEGF protein was 
determined using the Quantikine ELISA Human VEGF Immunoassay kit (DVE00; R&D 
Systems, Minneapolis, MN).  ESCs derived from a woman with endometriosis were 
plated in 6-well plates at 100,000 cells per well. Cells were treated with BCP (10-8M) for 
24 hours followed by IL-17 (z100465; Applied Biological Materials, Inc., Richmond, 
British Columbia, Canada) (50 ng/mL) alone or a combination of IL-17 (50 ng/mL) plus 
IL-6 (z100555; Applied Biological Materials, Inc.) (50 ng/mL) for 12 hours. The 
treatment media from each well (three replicates per treatment condition) was collected 
and frozen until analysis. The samples were thawed, and an ELISA was performed 
following the kit protocol. Each sample was added in duplicate. 
Immunohistochemical Staining of Endometrial Tissue for CB1 and CB2 
Immunohistochemical (IHC) staining for CB1 and CB2 receptors was completed 
on paraffin-embedded endometrial samples categorized as normal proliferative, normal 
mid-secretory and moderate endometriosis secretory.  
Endometrial samples were deparaffinized and rehydrated in a graded alcohol 
series then blocked with 2% normal horse serum in PBS. Samples were incubated with 
anti-CB1 (10006590; Cayman Chemical, Ann Arbor, MI; dilution: 1:200) or anti-CB2 
(SC-25494 Santa Cruz Biotechnologies, Santa Cruz, CA; dilution: 1:100) antibodies in 
2% normal horse serum in PBS overnight at 2°C. The next day, sections were incubated 
with secondary antibody conjugated to horseradish peroxidase (Vector Laboratories, 
Burlingame, CA) for 1 hour at room temperature. Immunoreactivity was detected using 
 
97 
 
diaminobenzidine (DAB-Vector Laboratories, Burlingame, CA) then counterstained with 
hematoxylin and cover slipped with Permount Mounting Medium (Fisher Chemical, 
Waltham, MA).  The slides were analyzed microscopically at 20X and 40X magnitudes 
and pictures were taken with a Nikon D200 camera (Nikon, Melville, NY) with 
microscopic lens. 
7-amino actinomycin D (7-AAD)  Cell Viability Assay 
 The effects of BCP stimulation on cell viability was measured in Ishikawa cells 
and primary endometrial stromal cells using 7-amino actinomycin D (7-AAD) viability 
dye (Beckman Coulter Life Sciences, Indianapolis, IN). Ishikawa and ESCs were plated 
in 6-well plates at 300,000 cells/well (2 mL volume/well) with 6 wells/treatment 
condition. Six-well plates were treated with different concentrations of BCP dissolved in 
ethanol for 24 hours. All plates were washed with PBS and cells were detached from 
wells with trypsin and collected into 15 mL conical tubes. The cells were centrifuged, 
supernatant decanted, and pellet resuspended in 1 mL PBS and quantified. Cells were 
diluted with PBS to a concentration of 5 million cells/mL. Five µL 7-AAD were added 
per well to U-bottomed 96-well plates with 5 µL PBS added to wells for unstained 
controls. To each well was added 100 µL sample and plates were incubated at room 
temperature in the dark for 20 minutes. Samples were analyzed via flow cytometry 
(CytoFLEX; Beckman Coulter Life Sciences). 
Statistical Analyses 
As each experiment was performed only once, valid statistical testing was not 
possible. 
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Results 
Effect of BCP on Estrogenicity 
Ishikawa cells are a model for assessing the estrogenic or anti-estrogenic potential 
of test compound. In the presence of E2, Ishikawa cells induce alkaline phosphatase 
which is assessed by spectrophometric measurement of p-nitrophenylphosphate produced 
above untreated control cells. A decrease in alkaline phosphatase induction indicates anti-
estrogenic activity.  
Figure 4.1. Dose-Response of BCP on the Alkaline Phosphatase Activity in Ishikawa 
Cells 
 
Figure 4.1. The cells were treated with BCP with or without estradiol (E2) (10-8M) for 72 
hours. Cells treated with the anti-estrogen ICI 182,780 (10-6M) represent a negative 
control for alkaline phosphatase induction. 
  
Effect of BCP on Alkaline Phosphatase Induction 
 BCP alone inhibited alkaline phosphatase induction of Ishikawa cells (Figure 4.1) 
below 50% of untreated control cells for all dosages following a 72-hour incubation. 
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Cells treated with estradiol (10-8M) were positively responsive above untreated control 
cells. Simultaneous treatment of Ishikawa cells with estradiol and all BCP dosages 
slightly reduced alkaline phosphatase response below estradiol alone. Cells treated with 
the anti-estrogen ICI 182,780 (10-6M) resulted in over 80% reduction of AlkP response.  
Figure 4.2. Dose-Response of BCP on the Alkaline Phosphatase Activity in RL95-2  
Cells 
 
Figure 4.2. The cells were treated with BCP with or without estradiol (E2) ( (10-8M) for 
72 Hours. Cells treated with the anti-estrogen ICI 182,780 (10-6M) represent a negative 
control for AlkP induction. 
 
BCP treatment alone at all doses tested showed no effect on alkaline phosphatase 
induction in RL95-2 cells following 72 hours incubation (Figure 4.2). The addition of ICI 
182,780 resulted in an inhibitory effect of 30%. Although RL95-2 cells are reported to be 
estrogen receptor positive, no stimulation of alkaline phosphatase activity was observed 
with the addition of E2 in the experiment.   
Effect of BCP on Cell Proliferation 
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 In Ishikawa cells (Figure 4.3), BCP alone inhibited proliferation in a dose-
response pattern at 48 and 72 hours. The effects of BCP plus estradiol (10-8M) were much 
more varied with a dose-response pattern of proliferation exhibited at 48 hours but not 72 
hours. BCP inhibits proliferation of RL95-2 cells at 72 hours at concentrations of 10-8M 
and 10-9M (Figure 4.4). Interestingly, these concentrations, with estradiol added, appear 
to increase proliferation.   
Figure 4.3. CyQUANT Proliferation Assay in Ishikawa Cells 
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Figure 4.3. Ishikawa cells were treated with BCP and BCP plus estradiol (10-8M). 
Control contained ethanol as vehicle. 
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Figure 4.4. CyQUANT Proliferation Assay in RL95-2 Cells 
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Figure 4.4. RL95-2 cells were treated with BCP and BCP plus estradiol (10-8M). Control 
contained ethanol as vehicle.  
 
In normal ESCs, BCP at a concentration of 10-8M exhibited no significant effects 
on proliferation (Figure 4.5), while endometriosis-positive ESCs exhibited a significant 
increase in proliferation on day six of treatment (Figure 4.6).   
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Figure 4.5. Trypan Blue Assay in Normal ESCs 
 
Figure 4.5. Normal ESCs were stimulated with BCP (10-8M) for six days. Control 
contained ethanol as vehicle. Cell number obtained at two, four, and six days post-
treatment.  
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Figure 4.6. Trypan Blue Assay in Endometriosis-Positive ESCs 
 
Figure 4.6. Endometriosis-positive ESCs were treated with BCP for six days. Control 
contained ethanol as vehicle. Cell number obtained at two, four, and six days post-
treatment. 
 
BCP (10-8M) resulted in a slight percent increase in normal and slight percent 
decrease in endometriosis-positive ESCs on day two and a slight decrease in both on day 
four compared to corresponding controls (Figures 4.7 & 4.8). On day six, both cell types 
(normal: 23.54%; endometriosis-positive: 18.78%) demonstrated a much larger percent 
increase in proliferation. 
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Figure 4.7. Trypan Blue Assay- Comparison of Normal and Endometriosis-Positive 
ESCs 
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Figure 4.7. Comparison of normal and endometriosis-positive ESCs proliferation in a 
trypan blue proliferation assay conducted over six days. Controls contained ethanol as 
vehicle. Cell numbers obtained at two, four, and six days post-treatment.  
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Figure 4.8. Percent Change in Proliferation in Normal and Endometriosis-Positive 
ESCs 
 
 
Figure 4.8. Comparison of percent change in ESC proliferation between normal cells and 
endometriosis-positive cells following BCP treatment. The percent change in ESC 
proliferation between control and BCP-treated (10-8M) cells was calculated for each cell 
type at each time point. Positive numbers indicate an increase in proliferation of the 
treated cells compared to the control while negative numbers indicate a decrease in 
treated cell proliferation. 
 
Effect of BCP on VEGF Production by ESCs 
Pretreatment of endometriosis-positive ESCs with BCP (10-8M) decreased 
cytokine-induced VEGF production by 31% compared to IL-17 (50 ng/mL) and by 17% 
compared to IL-17 (50 ng/mL) + IL-6 (50 ng/mL) (Figure 4.9). IL-17 + IL-16 stimulation 
increased VEGF production by 76%, IL-17 alone by 73% and IL-6 alone did not change 
VEGF levels compared to control. As this experiment was performed only once, valid 
statistical testing was not possible. 
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Figure 4.9. VEGF ELISA in Endometriosis-Positive ESCs 
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Figure 4.9. Cells were pretreated with BCP (10-8M) for 24 hours followed by 12-hour 
cytokine treatment (IL-17, 50 ng/mL; IL-6, 50 ng/mL). 
 
Immunohistochemistry Staining of Endometrial Tissue for CB1 and CB2 
CB1. 
The normal samples show that CB1 expression is high in the stroma during the 
proliferative phase (Figure 4.10 (A)) and decreases by the mid-secretory phase (C). 
Normal CB1 expression is minimal in the glands in both phases. The sample of moderate 
endometriosis in the secretory phase (D) exhibits intense glandular expression and 
moderate stromal expression, indicating that CB1 expression is upregulated in the 
glandular epithelium of women with endometriosis in the secretory phase.  
CB2. 
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CB2 expression is intense in the normal stroma during the proliferative phase 
(Figure 4.10 (B)) and decreases by the mid-secretory phase (E). In the normal glands, 
CB2 expression is low in both phases. CB2 is upregulated in the secretory phase in the 
stroma of the endometriosis sample (F) compared to the normal secretory phase control. 
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Figure 4.10. Immunohistochemical Analysis of CB1 and CB2 in Endometrial Tissue 
Samples 
 
Figure 4.10. A & B: normal proliferative; C & E: normal mid-secretory D & F: moderate 
endometriosis, secretory 
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Flow Cytometry 
Neither Ishikawa cell nor ESC viability differed from controls after 24 hour 
treatments with BCP at 10-8M, 10-9M and 10-10M in the 7-AAD viability flow cytometry 
experiments (Figure 4.11). 7-AAD is a DNA-intercalating dye that is unable to enter the 
cell membrane of viable cells, thus only dead and dying cells are stained. The CyQUANT 
proliferation assays indicated that 48-72 hours is the optimal treatment time, so these 
experiments will be repeated using those time points. Interestingly, a distinct cell 
population was identified in the ESC samples with peak fluorescence between the live 
and dead cell populations, likely indicating a pre-apoptotic population with some level of 
membrane disruption (Figure 4.11). There were higher percentages of cells in this 
population at all concentrations compared to control.  
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Figure 4.11. 7-AAD Flow Cytometry Analysis of ESCs Treated with BCP  
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Figure 4.11. Histogram and dot-plot of 7-AAD viability analysis of ESC treated for 24 
hours with BCP. Debris was eliminated using gate P1 set on the unstained control sample 
(A). Blue corresponds to cells not reactive to 7-AAD (viable), orange corresponds to cells 
fully reactive to 7-AAD (dead) and green corresponds to cells partially reactive to 7-
AAD (apoptotic). (A): unstained control; (B): stained control; (C): BCP 10-10M; (D): 
BCP 10-9M; (E): BCP 10-8M 
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Figure 4.12. Relative Expression of Cannabinoid Receptors in Ishikawa and RL95-2 
Cells 
 
 
Figure 4.12. Relative expression of CNR1(CB1) and CNR2(CB2) in Ishikawa and RL95-
2 cell lines. 
 
Discussion 
 
The purpose of this study was to examine the effects of the phyto-cannabinoid 
BCP on indicators of inflammation in endometriosis using a cell-culture model. 
Endometrial cancer cell lines Ishikawa (adenocarcinoma) and RL95-2 (adenosquamous 
carcinoma) were utilized as models for endometriosis. Both cell lines demonstrate 
markers expressed by normal endometrial epithelial cells including estrogen receptors α 
and β and progesterone receptor (Nishida, Kasahara, Kaneko, Iwasaki, & Hayashi, 1985; 
Way, Grosso, Davis, Surwit, & Christian, 1983). 
rtPCR analysis of Ishikawa and RL95-2 cells (Figure 4.12) demonstrated that 
neither cell line expresses CNR2 mRNA, which encodes CB2, the target receptor for 
BCP. This finding may explain the results from experiments employing BCP treatment 
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on these cell lines prior to rtPCR (Figures 4.1-4.4). While these cell lines are ineffective 
for testing the cannabinoid BCP due to their lack of CB2 receptor, they do express CB1. 
RL95-2 cells highly express CB1, making this line a potential model for future 
experiments using other cannabinoids exhibiting CB1-reactivity.  
IL-6 and IL-17 were used in the VEGF study as both have been shown to induce 
VEGF expression. In this study, BCP was found to inhibit IL-17-induced VEGF 
expression in ESCs, but not when IL-17 was combined with IL-6. Angiogenesis, driven 
by VEGF, is a significant feature of endometriosis. Vascularization is normal and 
necessary in the endometrium for proper reproductive functions, but the vascularization 
of endometriosis implants allows them to survive and flourish by connecting to the local 
blood supply for sustenance. (McLaren, 2000; Taylor, Lebovic, & Mueller, 2002). 
VEGF, operating via a concentration gradient, encourages blood vessels to divide and 
grow towards the implant. VEGF expression is induced by cytokines through the Janus 
kinase (JAK)/STAT3 pathway. Cytokines of the IL-6 family, produced by local immune 
cells, are the primary inducers of VEGF production. IL-6 protein is produced by IL-6 
gene, which maps to chromosome 7p15.3 (NCBI). Other non-IL-6 family cytokines may 
also be involved in VEGF production. Abnormal levels of IL-6, VEGF and aberrant 
STAT3 activation are reported in endometriosis (B. G. Kim et al., 2015). Further, VEGF 
receptors are upregulated on lesions (Di Carlo et al., 2009; Donnez, Smoes, Gillerot, 
Casanas-Roux, & Nisolle, 1998; Takehara et al., 2004).  
IL-17 was only recently identified as a mediator of inflammation in endometriosis 
(Ahn et al., 2015). It is primarily produced by local Th17 cells. Alone, IL-17 is a weak 
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inducer of transcription of proinflammatory mediators, including VEGF, via the NFκB, 
MAPK and C/EBP pathways. IL-17 appears to exert potent proinflammatory effects by 
synergizing with other cytokines, such as IL-1β, IL-22, IFN-γ and TNF-α, all of which 
are elevated in endometriosis (Beringer, Thiam, Molle, Bartosch, & Miossec, 2018). IL-
17 acts to stabilize the mRNA of these more powerful cytokines to increase the half-life 
and the likelihood of their translation and thus prolong the inflammatory response 
(Hartupee, Liu, Novotny, Li, & Hamilton, 2007). In line with this, Hirata et al. (2008, 
2011) reported that IL-17A and IL-17F synergized with TNF-α to increase levels of 
COX-2 and IL-8 by ESCs (Hirata et al., 2008, 2011). 
Interestingly, IL-17 alone was a greater inducer of VEGF than was IL-6 alone, 
which was similar to control. BCP decreased the VEGF levels of IL-17 treatment, but not 
when IL-6 was added. Either IL-17 and IL-6 are exhibiting synergistic effects, though 
there is scant literature to support that these cytokines synergize, or BCP blocks one of 
the pathways involved in IL-17-mediated VEGF production (NFκB, MAPK, C/EBP), but 
not those of IL-6 (STAT3). In contradiction to these findings, Kim et al (2013) found that 
BCP prevented STAT3 phosphorylation in three cancer cell lines (C. Kim et al., 2013). 
Overall, the findings showed mixed results regarding the effectiveness of BCP as 
a therapeutic option for endometriosis. Multiple experiments using BCP were performed, 
but not replicates of the same experiment, so valid statistical testing was not possible. 
Neither of the cancer cell lines used, both of which are commonly used in endometriosis 
research, possess CB2 receptors, making them an ineffective model in which to test BCP. 
CB2 does appear to be present in endometrial tissue samples and is upregulated in 
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endometriosis-positive samples. BCP decreased levels of IL-17-induced VEGF in 
primary ESCs from a uterine tissue sample with endometriosis. Therefore, additional 
research using primary cell cultures is needed.  
Analysis by rtPCR revealed that neither cell line expresses CB2, the receptor 
through which BCP acts. As BCP does appear to decrease estrogenicity and proliferation 
in Ishikawa cells when exogenous estradiol is not added, BCP may be working through 
some mechanism besides CB2, though further studies are necessary to identify what that 
may be.  
Many experiments using BCP were performed in the study, but each was only 
carried out one time. Lacking adequate replication, valid statistical analysis could not be 
done. Endometrial stromal cells were extracted from samples of two individuals only 
(one endometriosis-positive, one endometriosis-negative). Both were Caucasian women 
in their late 20’s. The small sample size prevents appropriate statistical testing and the 
lack of ethnic diversity among samples prevents generalizability of the results.  
More research into identifying any alternate mechanisms through which BCP may 
act are recommended. The Ishikawa and RL95-2 cell lines do not express CB2, thus 
additional research should be conducted in other cell lines such as the endometrial 
adenocarcinoma lines HEC-1A or HEC-1B. Additionally, experiment replication 
allowing for statistical testing is needed. 
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CHAPTER FIVE  
SUMMARY, LIMITATIONS AND RECOMMENDATIONS  
The interdisciplinary Healthcare Genetics PhD program was developed to expose 
students to a broad array of genetics-focused disciplines in an effort to produce graduates 
prepared to tackle complex genetics-based healthcare issues. The healthcare genetics 
(HCG) conceptual model developed by individuals associated with the program was 
described in Chapter One. In this model, the field of healthcare genetics is composed of 
five core constructs: Clinical Practice, Education, Environment, Ethical/Legal/Social 
Implications (ELSI) and Research. This dissertation was guided by constructs of the 
HCG framework and focused on Clinical Practice, Education and Research. 
Chapter Two 
HCG Model Application and Significance 
Chapter Two, Computational Investigation of the Missense Mutations in DHCR7 
Gene Associated with Smith-Lemli-Opitz Syndrome, employs the Research construct in 
which biophysics and computer modeling are applied to explore protein stability. Based 
on in silico analyses, the findings support other studies that pathogenic DHCR7 mutations 
tend to occur in highly conserved and trans-membrane spanning regions of the protein. 
However, new results from this study suggest that the non-classified mutation R228Q 
associated with Smith-Lemli-Opitz syndrome (SLOS) is actually pathogenic.  
The study in Chapter Two also identified: a) SLOS patients possessing the R228Q 
variant may exhibit more severe symptoms than other patients with the same variant; and 
b) the encoded protein will be unstable and less effective in its physiological role in 
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cholesterol synthesis. If future studies confirm that R228Q is, in fact, pathogenic, then 
HCPs in the clinical setting may use this information to help carriers of this mutation 
make family planning and/or personal health decisions.  These two exemplars 
incorporated the Clinical Practice construct in this research. 
Limitations 
The study was based on the current published structure of the integral membrane 
sterol reductase from M. alcaliphilum with only 37% sequence identity to the human 
enzyme DHCR7. This experimental structure possessed the greatest homology to human 
DHCR7 available at the time the research was conducted. The eventual development of a 
structure with greater homology may further refine these research findings.  
The second obstacle is that the DHCR7 is a trans-membrane protein, in which 
stability is difficult to predict. Membrane-embedded proteins consist of areas buried in a 
hydrophobic lipid bilayer with other areas exposed to water, resulting in a heterogeneous 
environment that is difficult to model accurately. Membrane proteins make up more than 
40% of the protein structure database (Kroncke et al., 2016), however only 1% of 
membrane proteins have their 3D structure solved experimentally.  
Future Research 
Recommendations for future research include: 
a) Development of novel methods to predict membrane protein dynamics 
due to the limitations of current methods, as noted above;  
b) Online publication of the crystal structure of the human DHCR7 
enzyme; 
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genomic studies on individuals with the DHCR7 variant; and, 
 
c)  Further study on the symptoms associated with SLOS. 
Chapter Three 
HCG Model Application and Significance 
Chapter Three, The Emerging Role of Interleukin 17 (IL-17) in the Pathogenesis 
of Endometriosis, is a review of the literature exploring the role of interleukin 17 (IL-17) 
and T helper 17 (Th17) cells in the common gynecological disease endometriosis. 
Endometriosis affects 10% of women of reproductive age, yet its variable presentation 
makes it difficult to diagnose. Diagnosis may take 8-12 years in some cases (Ballard, 
Lowton & Wright, 2006). One goal of this review is to better educate healthcare 
professionals about the signs and symptoms of the disease to lessen the time between a 
woman’s onset of symptoms and diagnosis. An overview of the structure and function of 
IL-17, as well as a review of the role of IL-17 in endometriosis is described. Finally, 
some potential IL-17-targeted therapies are explored which may, in the future, provide 
relief for women suffering from endometriosis. This chapter aligns with the HCG 
constructs of Education and Clinical Practice. 
Limitations 
The main limitation of this chapter is its structure as a subjective narrative review, 
rather than a systematic review. The scope of discussion was limited by page number, so 
a detailed discussion of activation of the NF-κB, MAPK and C/EPB pathways by IL-17 
was not included.  
Future Research  
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Recommendations for future research include: 
a) A more rigorous and comprehensive systematic review or meta-
analysis of the involvement of IL-17 in endometriosis; 
b) A review with inclusion of current and upcoming IL-17-targeted 
therapies indicated for other conditions whose therapeutic effects 
might be studied in endometriosis; and, 
c) A more detailed review of the interactions of IL-6 with IL-17 and 
Th17 cells in endometriosis would be applicable, due to the role IL-6 
plays in the production of IL-17 through the activation of Th17 cells. 
Chapter Four 
HCG Model Applications and Significance 
Chapter Four, Assessment of Beta-Caryophyllene (BCP) for the Treatment of 
Endometriosis Using an In Vitro Approach, which details experiments examining the 
effect of the cannabinoid beta-caryophyllene (BCP) on a cell model of endometriosis. In 
this research, the effects of BCP on inflammatory markers was examined in two cancer 
cell lines (Ishikawa and RL95-2), and in primary human endometrial stromal cells 
(ESCs).  It was anticipated that BCP, which has been shown to initiate an anti-
inflammatory phenotype by selectively binding the cannabinoid receptor CB2, would 
decrease estrogenicity (alkaline phosphatase activity), cell proliferation, and VEGF 
production. This study, whose findings could inform the development of novel therapies 
for endometriosis, may have Clinical Practice implications. Chapter Four incorporates the 
HCG constructs of Research and Clinical Practice. 
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The study in Chapter Four identified: a) BCP downregulates alkaline phosphatase 
in Ishikawa cells in the absence of exogenous estradiol; b) BCP inhibits Ishikawa cell 
proliferation in a dose-dependent manner; c) BCP decreased IL-17-induced VEGF 
production in endometriosis-positive endometrial stromal cells in the absence of IL-6; 
and d) neither Ishikawa cells nor RL95-2 cells express CB2, the receptor through which 
BCP has been shown to act. As BCP does appear to decrease alkaline phosphatase 
activity and proliferation in Ishikawa cells when exogenous estrogen is not added, BCP 
may be working through some alternate mechanism. The cytokine IL-17 is weakly 
capable of inducing VEGF production on its own, but functions to synergize with other 
cytokines to stabilize their mRNA and prolong the half-lives of their transcripts. IL-17 
may act in concert with IL-6 in endometriosis-positive stroma cells, though no support 
for synergy between IL-17 and IL-6 was identified in the literature. 
Limitations 
Though many experiments were performed in the study, each was replicated only 
one time, as directed by the mentor. This low number of replications did not allow for 
valid statistical testing; thus, these results serve as representations of the effects of BCP 
in endometriosis only. Endometrial stromal cells were extracted from samples of two 
individuals (one endometriosis-positive, one endometriosis-negative). The small sample 
size does not allow appropriate statistical testing or generalizability of the results.  
Future Research   
Recommendations for future research include: 
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a) Identification of alternate mechanisms of BCP activity as it was observed 
to affect estrogenicity and proliferation in Ishikawa cells, despite their lack 
of CB2 receptor expression;  
b) Investigate the potential synergy between IL-17 and IL-6; and, 
c) Replicate the experiments enough times to allow for statistical testing.  
The results could suggest which mechanisms show promise for treatment 
of endometriosis. 
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Appendix A 
Institutional Review Board (IRB) Documents 
November 26, 2014 
Bruce A. Lessey, 
MD, PhD Attn: 
Cheryl Myers, RN  
University Medical Group  
Department of Obstetrics and Gynecology 
Greenville Health System  
890 West Faris Road, Suite 470  
Greenville, SC  29605  
RE:   IRB File # Pro00038040 
Study Title: Endometrial Biomarkers in Fertile Controls 
Items Submitted for IRB Review:   Protocol Dated 10/15/2014; 
Consent Form; Study Prescreening 
Handout  
Dear Dr. Lessey: 
On November 13, 2014, the Institutional Review Board/Committee-A (IRB) of the 
Greenville Health System reviewed and approved the items listed above on your research 
study contingent upon a consent form modification. This modification was received in the 
IRB office on 11/20/2014 and final review/approval was given via expedited review on 
11/26/2014.   
Your study will expire on November 12, 2015.  It is the investigator’s 
responsibility to make sure the proper reapproval information is submitted 
to the IRB.  This information must be submitted to the IRB in October 2015.    
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Please keep in mind the following requirements of the Institutional Review Board: 
1. All participants must sign a copy of the attached IRB-stamped “approved”
consent form before they can be enrolled in this study.  Please use this stamped
“approved” consent form to make copies for each participant.
2. Only the principal investigator or co-investigator can obtain consent from the
participant.
3. The participant must sign and date the consent form in the presence of a witness.
4. A report to the IRB is required at the end of the approved time period giving the
results of the participants involved in the study, the status of the study and
whether or not renewed approval is desired.
5. Immediate notification must be sent to the IRB of any advertisements,
modification of the Form 1572, as well as all revisions, changes, or amendments
to the protocol or consent form.
6. Notification must be sent to the IRB within five (5) working days of any events
required to be reported by the ORCA Policy HRPP Number 16.01.
7. The investigator must be sure that all consent forms are signed, dated and
witnessed and placed in the participant’s study record prior to study participation.
The original should be retained in the participant’s study record at the clinical
research site. Case histories (patient charts/records) will also document that
Informed Consent was obtained prior to the subject’s participation in the study.
Bruce A. Lessey, MD, PhD 
November 26, 2014  
Page 2  
8. A signed copy of the consent form must be given to the person signing the form
and a copy placed in the medical record if the study involves any type of hospital
stay.
9. Please remember to use the GHS Study Drug Request Form for all participants
entered in this study, when applicable.  Your cooperation in this helps the
pharmacy to better serve you.  This form can purchased from the Supply and
Distribution Center (Karen Corwin at 455-7819), Form Number A23914.
The IRB has written procedures for the initial and continuing review of research studies; 
prepares written minutes of convened meetings; and retains records pertaining to the 
review and approval process.  This is done in compliance with requirements defined in 
the Code of Federal Regulations (21 CFR Parts 50, 56, 312 and 812; 45 CFR Parts 46 and 
164) and ICH (International Conference on Harmonisation) guidance relating to GCP
(Good Clinical Practice).
Thank you for your assistance in this matter.  Should you have any questions, please do 
not hesitate to call the IRB office at (864) 455-4984.  
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Sincerely, 
Christopher C. Wright, MD, Chairperson  
Institutional Review Board/Committee-A 
Employee 
Services Center 
701 Grove Road  
Greenville, SC  29605  
CCW/ks 
Attachment 
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November 10, 2016 
Bruce A. Lessey, 
MD, PhD Attn: 
Cheryl Myers, RN  
University Medical Group  
Department of Obstetrics and Gynecology 
Greenville Health System  
890 West Faris Road, Suite 470  
Greenville, SC  29605  
RE:   IRB File # Pro00038040 
Study Title: Endometrial Biomarkers in Fertile Controls 
 Items Submitted for IRB Review:   Protocol and Consent Form 
Continuing Review  
Dear Dr. Lessey: 
On November 10, 2016, the Institutional Review Board/Committee-A (IRB) of the 
Greenville Health System reviewed your research study.  Full committee approval of the 
above-mentioned items was given for one year.  
Your study will expire on November 9, 2017.  It is the investigator’s 
responsibility to make sure the proper reapproval information is submitted 
to the IRB.  This information must be submitted to the IRB in October 2017.  
The same requirements as previously outlined for you by the IRB remain in effect as long 
as the study is ongoing.  Please refer to your initial approval letter for these requirements. 
Thank you for your assistance in this matter.  If you have any questions, please feel free 
to call the IRB Office at (864) 455-4984.    
Sincerely, 
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Christopher C. Wright, MD, Chairperson  
Institutional Review Board/Committee-A 
Employee Services Center  
701 Grove Road  
Greenville, SC  29605  
CCW/ks 
Attachment 
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October 13, 2017 
Bruce Lessey, MD, PhD  
Attn: Cheryl Myers, RN  
University Medical Group  
Department of Obstetrics and Gynecology  
Greenville Hospital System University Medical Center 
890 West Faris Road, Suite 470  
Greenville, SC  29605  
RE: IRB File # Pro00038040 
Study Title: Endometrial Biomarkers in Fertile Controls 
 Items Submitted for IRB Review:   Protocol and Consent Form 
Continuing Review  
Dear Dr. Lessey: 
On October 12, 2017, the Institutional Review Board/Committee-A (IRB) of the 
Greenville Health System reviewed your research study.  Full committee approval of the 
above-mentioned items was given for one year.  
Your study will expire on October 11, 2018.  It is the investigator’s 
responsibility to make sure the proper re-approval information is submitted 
to the IRB.  This information must be submitted to the IRB in September 2018.  
The same requirements as previously outlined for you by the IRB remain in effect as long 
as the study is ongoing.  Please refer to your initial approval letter for these requirements.  
Thank you for your assistance in this matter.  If you have any questions, please feel free 
to call the IRB Office at 864-455-8997.  
Sincerely, 
Christopher C. Wright, MD, Chairperson 
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Institutional Review Board/Committee-A 
Employee Services Center  
701 Grove Road  
Greenville, SC  29605  
CCW/akg 
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September 13, 2018  
  
Bruce Lessey, MD, PhD  
Attn: Cheryl Myers, RN  
  
RE: IRB File # Pro00038040  
 Study Title: Endometrial Biomarkers in Fertile Controls  
 Items Submitted for IRB Review:   Permanent Closure   
  
Dear Dr. Lessey:  
  
On September 12, 2018, the Chairman of the Institutional Review Board/Committee-A of 
the Greenville Health System reviewed the above-mentioned item that was presented for 
expedited review.  The Chairman accepted this as information and a copy will be kept in 
the IRB file.   
  
Thank you for your assistance in this matter.  Should you have any questions, please do 
not hesitate to call the IRB office at 864-455-8997.  
  
Sincerely,  
  
Christopher C. Wright, MD, Chairman  
Institutional Review Board /Committee-A  
Employee Services Center  
701 Grove Road  
Greenville, SC  29605  
  
CCW/akg  
  
 
  
 
144 
 
Appendix B 
Permissions for Use 
Permission to use Figure 3.2. IL-17 Signaling 
Request to use adapted figure from Amatya et al., 2017 
3 messages 
 
Rebecca Myers <rlmyers@g.clemson.edu> Thu, Oct 18, 2018 at 2:20 PM 
To: sarah.gaffen@pitt.edu 
Hello Dr. Gaffen, 
 
I have developed a figure similar to Fig 3 (Activation of IL-17 signal transduction) in your published 
article "IL-17 signaling: The yin and the yang". 2017. Trends in Immunology, 38(5), 310–322. 
I would like to incorporate the figure into a chapter of my dissertation stating "adapted from Amatya, 
Garg, & Gaffen, 2017)" in the caption, with a citation of your paper in the references. Would this be 
acceptable? 
 
Please find my version of the figure attached.  
 
Thank you for your consideration, 
 
Rebecca Myers, PhD (c)  
Healthcare Genetics Doctoral Program 
Clemson University 
 
 
--  
Rebecca Myers 
PhD candidate, Healthcare Genetics 
Clemson University 
rlmyers@clemson.edu 
(803) 709-1531 
 
 
 
 Adapted from Amatya et al 2017_IL-17 figure.docx 
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Gaffen, Sarah L <sarah.gaffen@pitt.edu> Thu, Oct 18, 2018 at 2:34 PM 
To: Rebecca Myers <rlmyers@g.clemson.edu> 
How nice of you to ask!  Yes absolutely.   
 
Sarah 
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Sent from my iPhone  
(Sarah Gaffen) 
[Quoted text hidden] 
<Adapted from Amatya et al 2017_IL-17 figure.docx> 
 
 
Rebecca Myers <rlmyers@g.clemson.edu> Thu, Oct 18, 2018 at 2:37 PM 
To: sarah.gaffen@pitt.edu 
Great, thank you! 
[Quoted text hidden] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
MDPI Open Access: Terms of Use (Chapter Two) 
MDPI AG Postfach CH–4020 Basel Switzerland Tel. +41 61 683 77 34 Fax +41 61 302 89 18 www.mdpi.com  
 
 MDPI AG Basel • Beijing • Wuhan • Barcelona • Belgrade www.mdpi.com  
 
 Terms of Use  
§ 1 These Terms of Use govern the use of the MDPI websites or any other MDPI online 
services you access. This includes any updates or releases thereof. By using our online 
services, you are legally bound by and hereby consent to our Terms of Use and Privacy 
Policy. These Terms of Use form a contract between MDPI AG, registered at St. Alban-
Anlage 66, 4052 Basel, Switzerland (“MDPI”) and you as the user (“User”). These Terms 
of Use shall be governed by and construed in accordance with Swiss Law, applicable at 
the place of jurisdiction of MDPI in Basel, Switzerland.  
§ 2 Unless otherwise stated, the website and affiliated online services are the property of 
MDPI and the copyright of the website belongs to MDPI or its licensors. You may not 
copy, hack or modify the website or online services, or falsely claim that some other site 
is associated with MDPI. MDPI is a registered brand protected by the Swiss Federal 
Institute of Intellectual Property.  
§ 3 Unless otherwise stated, articles published on the MDPI websites are labeled as 
“Open Access” and licensed by the respective authors in accordance with the Creative 
Commons Attribution (CC-BY) license. Within the limitations mentioned in §4 of these 
Terms of Use, the “Open Access” license allows for unlimited distribution and reuse as 
long as appropriate credit is given to the original source and any changes made 
compared to the original are indicated.  
§ 4 Some articles published on this website (especially articles labeled as “Review” or 
similar) may make use of copyrighted material for which the author(s) have obtained a 
reprint permission from the copyright holder. Usually such reprint permissions do not 
allow author(s) and/or MDPI to further license the copyrighted material. The licensing 
described in §3 of these terms and conditions are therefore not applicable to such kind 
of material enclosed within articles. It is the User’s responsibility to identify reusability of 
material provided on this website, for which he may take direct contact with the authors 
of the article.  
§ 5 You may register or otherwise create a user account, user name or password (your 
“Registration”) that allows you to access or receive certain content and/or to participate 
or utilize certain features of our online service, including features in which you interact 
with us or other users. You represent and warrant that the information provided in your 
Registration is accurate to the best of your knowledge. You are responsible for the use 
of any password you create as part of your Registration and for maintaining its 
confidentiality, and you agree that MDPI may use this password to identify you. We 
reserve the right to deny, terminate or restrict your access to any content or feature 
reached via such Registration process for any reason, at our sole discretion. MDPI 
reserves the right to block or to terminate the User’s access to the website at any time 
and without prior notice.  
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§ 6 The MDPI website and online services may provide links to other websites or 
external resources. As part of these Terms of Use, you acknowledge that MDPI is in not 
responsible for the availability of such external sites or resources, and that MDPI is not 
liable for any content, services, advertising, or materials available from such external 
sites or resources. 
§ 7 The website may contain advertising. MDPI does not endorse any responsibility of 
any kind for the content of the advertisement or sponsorship or the advertised product or 
service, which is the responsibility of the advertiser or sponsor, unless the advertised 
product or service is offered by MDPI.  
§ 8 There is no warranty for the website and its content, to the extent permitted by 
applicable law. MDPI, the copyright holders and/or other parties provide the website and 
its content “as is” without representations or warranties of any kind, either expressed or 
implied, including, but not limited to, the implied warranties of merchantability, 
satisfactory quality and fitness for a particular purpose relating to this website, its content 
or any to which it is linked. No representations or warranties are given as to the accuracy 
or completeness of the information provided on this website, or any website to which it is 
linked.  
§ 9 In no event, unless required by applicable law shall MDPI, its employees, agents, 
suppliers, contractors or any other party, be liable to the User for any damages of any 
nature, including any general, special, incidental or consequential damages, loss, cost, 
claim or any expense of any kind arising out of the use, inability to access, or in 
connection with the use of the website, its content and information, even if the User has 
been advised of the possibility of such damages.  
§ 10 MDPI reserves the right to change these Terms of Use at any time by posting 
changes to this page of the website without prior notice. Please check these Terms of 
Use periodically for any modifications. Your continued use of any Service following the 
posting of any changes will mean that you have accepted and agreed to the changes.  
§ 11 Basel, Switzerland shall be the place of jurisdiction for all legal disputes arising of 
these Terms of Use, even if the Customer has her/his domicile outside of Switzerland.  
§ 12 Swiss law applicable at the place of jurisdiction of MDPI shall apply exclusively.  
§ 13 If any provisions of the Terms of Use should be found invalid, this shall not affect 
the validity of the remaining provisions. In any such case, the contracting parties shall 
negotiate on the invalid clause to substitute by a valid arrangement as close as possible 
to the original provision.  
 
These Terms of Use were last updated on 01. March 2017  
MDPI AG, St. Alban-Anlage 66, CH-4052 Basel, Switzerland 
 
 
